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Epilepsy is a disease characterized by abnormal brain activity and a predisposition to
generate epileptic seizures, leading to neurobiological, cognitive, psychological, social,
and economic impacts for the patient. There are several known causes for epilepsy; one of
them is the malfunction of ion channels, resulting from mutations. Voltage-gated sodium
channels (NaV) play an essential role in the generation and propagation of action potential,
and malfunction caused by mutations can induce irregular neuronal activity. That said,
several genetic variations in NaV channels have been described and associated with
epilepsy. These mutations can affect channel kinetics, modifying channel activation,
inactivation, recovery from inactivation, and/or the current window. Among the NaV
subtypes related to epilepsy, NaV1.1 is doubtless the most relevant, with more than 1500
mutations described. Truncation and missense mutations are the most observed
alterations. In addition, several studies have already related mutated NaV channels with
the electrophysiological functioning of the channel, aiming to correlate with the epilepsy
phenotype. The present review provides an overview of studies on epilepsy-associated
mutated human NaV1.1, NaV1.2, NaV1.3, NaV1.6, and NaV1.7.
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Epilepsy is a disease known worldwide, affecting around 70 million people in the world (Thijs et al.,
2019). It has been considered a disease and no longer a disorder or a family of disorders since 2014
by International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)
(Falco-Walter et al., 2018). Epilepsy is conceptually defined as a disease in which an individual has at
least two unprovoked or reflex seizures in a period greater than 24 h apart, one unprovoked or reflex
seizure and a probability of having another seizure similar to the general recurrence risk after two
unprovoked seizures (greater than or equal to 60%) over the next ten years or an epilepsy syndrome
(Fisher et al., 2014).
When abnormal brain activity begins in one or more identified regions, epilepsy is
called focal, whereas, when it occurs in both hemispheres with a wide distribution, it is
called generalized. Finally, when it cannot be classified as either focal or generalized, it is called
unknown (Devinsky et al., 2018).in.org August 2020 | Volume 11 | Article 12761
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income levels (Saxena and Li, 2017). Understanding the etiology
of epilepsy is crucial for clinical management of patients and for
conducting neurobiological research that will direct future
therapies (Thomas and Berkovic, 2014). The ILAE Task Force
has defined six etiologic categories; they are not hierarchical and
more than one might often apply (structural, genetic, infectious,
metabolic, immune, and unknown) (Falco-Walter et al., 2018).
Among those genetically caused, it is possible to identify
several epilepsy-related genes (Lindy et al., 2018). For example,
voltage-gated potassium channel, voltage-gated calcium channel
and voltage-gated chloride channel genes, GABA receptors,
nicotinic acetylcholine receptors, polymerase (DNA) Gamma
genes and voltage-gated sodium channel genes (Deng
et al., 2014).
Voltage-gated sodium channels (NaV) can be found mainly
in the central nervous system (CNS), peripheral nervous systems
(PNS), skeletal, and cardiac muscles (Huang et al., 2017). NaVs
are distributed throughout the body and play an important role
in the generation and propagation of action potential (Wang
et al., 2017b). Structurally, NaVs are composed by an a subunit
organized in four homologous ligated domains (DI-DIV), each
domain composed by six transmembrane segments (S1-S6), and
one or more b subunits associated by non-covalent interactions
or disulfide bond (Abdelsayed and Sokolov, 2013; Gilchrist et al.,
2013; Catterall, 2017; Bouza and Isom, 2018; Jiang et al., 2020).
The domains of an a subunit present a high degree of
conservation with each other, presenting the region known as
the voltage sensor domains (VSD) located in transmembranes
S1-S4, especially S4 helix, which contains positively charged
residues, and the pore-forming (PM) domain located in S5-S6
segments, structuring a four VSD around a central pore (Ahern
et al., 2016).
The S4 helix of DI, DII, and DIII domains moves faster than
the S4 helix of DIV during membrane depolarization, and this
asynchronous movement is an essential feature in the steady
activation voltage-dependent process, which provokes
movement of S4-S5 intracellular links followed by the
displacement of the S6 segments to initiate Na+ influx
(Goldschen-Ohm et al., 2013; Oelstrom et al., 2014). The
movement of the S4 helix of DIV initiates the process of fast
inactivation, since the movement of the voltage sensor in domain
DIV is associated with the displacement of an intracellular loop
between DIII and DIV within an IFM (isoleucine, phenylalanine,
and methionine) motif that binds intracellular to PM and
terminate Na+ influx (Capes et al., 2013; Clairfeuille et al.,
2019). A second type of reversible inactivation occurs after
repetitive or prolonged stimulation and results in steady-state
inactivation whose asymmetric movement of S6 segments
collapses the pore (Payandeh et al., 2012; Zhang et al., 2012;
Gamal El-Din et al., 2013; Silva and Goldstein, 2013; Ghovanloo
et al., 2016). Consequently, electrophysiological changes such as
increased current density, shifting steady-state activation, and
inactivation to negative and positive values, respectively,
enhanced persistent current, accelerated recovery from
inactivation, and delayed fast inactivation can cause gain-of-Frontiers in Pharmacology | www.frontiersin.org 2function (GoF) in the channel. Also, decreased current density,
positive shift in steady-state activation, negative shift in steady-
state inactivation, and slower recovery from inactivation can
cause loss-of-function (LoF) (Mantegazza et al., 2005; Liao et al.,
2010; Lossin et al., 2012; Catterall, 2014b; Vanoye et al., 2014;
Wagnon et al., 2017; Yang et al., 2018; Zaman et al., 2018;
Wengert et al., 2019; Zhang S. et al., 2020).
Currently, there are nine different alpha subtypes of NaVs
(NaV1.1-NaV1.9), and mutations in these channels can cause
diseases known as channelopathies (Catterall et al., 2010).
NaV1.1 (SCN1A), NaV1.2 (SCN2A), NaV1.3 (SCN3A), NaV1.6
(SCN8A) and NaV1.7 (SCN9A) are genes whose mutations are
related to epilepsy. So far, there is no correlation of mutations in
NaV1.4 (SCN4A), NaV1.5 (SCN5A), NaV1.8 (SCN10A), and
NaV1.9 (SCN11A) with epilepsy, which is to be expected, since
these channels are mainly expressed in skeletal muscles, cardiac
tissues, dorsal root ganglia, trigeminal sensory neurons,
nociceptive neurons of the dorsal root and trigeminal ganglia,
respectively (Brunklaus et al., 2014). Both a and b subunits
(SCN1B) have been reported as the cause of epilepsy phenotype
(Meisler et al., 2010; Kaplan et al., 2016).
NaV channels rank amongst the 2% most conserved
proteins in the human genome, with an extremely low rate
of coding variation, accounting for nearly 5% of known
epileptic encephalopathies (Petrovski et al., 2013; Mercimek-
Mahmutoglu et al., 2015; Lek et al., 2016; Heyne et al.,
2019). Pathogenic mutated residues are situated in the
highly evolutionarily conserved portions of the channel:
transmembrane segments, intracellular inactivation gate loop,
and the proximal 2/3 of the C-terminal domain (Blanchard
et al., 2015; Wagnon and Meisler, 2015). The final 1/3 portion
of the C-terminal and cytoplasmic interdomain loops 1 and 2
are less conserved (Denis et al., 2019). The proximal 2/3 of the
C-terminal are involved in the interaction of several binding
sites for proteins and accessory molecules, like beta subunits b1
and b3, fibroblast growth factors (molecules implicated in
neural development), calmodulin (regulatory protein in
neuronal function and hyperexcitability) and G protein
(Bähler and Rhoads, 2002; Spampanato, 2004; Wittmack
et al., 2004; Laezza et al., 2009; Yang et al., 2010). Moreover,
the C-terminal has been shown to interact with the inactivated
channel via ionic interaction between its positively charged
residues and negatively charged residues at the inactivation
gate. A shift in any of the charges can brake electrostatic
interaction and affect normal channel inactivation (Nguyen
and Goldin, 2010; Shen et al., 2017; Johnson et al., 2018).
The N-terminal region seems to play a more important role
on protein trafficking than on channel activity. This domain
interacts with the light chain of microtubule-associated protein
MAP1B, facilitating the traffic of the NaV channel to the
neuronal cell surface (O’brien et al., 2012; Blanchard et al.,
2015). In addition, mutation in the N-terminal leads to protein
retention in the endoplasmic reticulum (Sharkey et al., 2009).
Newer genomic approaches, especially next generation
sequencing (NGS), improve the rate and reduce the costs
associated with genetic epilepsy diagnosis, since traditionalAugust 2020 | Volume 11 | Article 1276
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and diagnostic yield is incredibly low (Veeramah et al., 2013;
Allen et al., 2016; Sands and Choi, 2017; Orsini et al., 2018). The
use of gene panels and whole-exome sequencing (WES) provides
a powerful tool to change the paradigm of genetic epilepsy
diagnosis (Ng et al., 2010; Clark et al., 2018). These techniques
have been widely used to elucidate suspected inherited
neurological diseases in the last years, contributing to
dramatically increase the number of patients diagnosed with
genetic epilepsy. Both mendelian and de novo genetic epilepsy
can be detected with these methods, but doubtless, de novo
mutations are the most prevalent mutations related to epilepsy-
related voltage-gated sodium channel mutations.
Gene therapy is promising as an effective approach to treat
genetic diseases. Personalized epilepsy therapies are in
development and have shown promising results, ranging from
antisense oligonucleotides and small peptides to modulation of
gene expression through epigenetics (Riban et al., 2009; Tan
et al., 2017; Stoke Therapeutics, 2018; Perucca and Perucca,
2019). Even eating habits may be related to an improvement in
the patient's clinical condition. Ketogenic diet has been described
as an effective treatment in epilepsy (Gardella et al., 2018).
Moreover, the combination of traditional antiepileptic drugs
with new compounds displayed a synergic and improved
efficacy, since these molecules do not compete for the same
interaction site (Bialer et al., 2018). Each specific epilepsy-related
NaV isoform will be presented and discussed in detail in the
following sections.NaV MUTATIONS
NaV1.1
The SCN1A gene encodes for the a subunit NaV1.1, and is
allocated at the 2q24.3 chromosome between 165,984,641 and
166,149,161 base pairs, same gene cluster of SCN2A-SCN3A
genes, being the most frequent target of mutation in genetic
epilepsy syndromes (OMIM#182389) (Malo et al., 1991; Malo
et al., 1994; Catterall et al., 2010). NaV1.1 is widely expressed in
the CNS, predominant in inhibitory GABAergic interneurons,
regulating neuronal excitability, and the reduction of its activity
is one of the factors that cause epileptic diseases due to imbalance
between inhibition and excitation (Yu et al., 2006; Verret et al.,
2012; Tai et al., 2014; Rubinstein et al., 2015).
Epilepsy syndromes, such as generalized epilepsy with febrile
seizures plus (GEFS+; Online Mendelian Inheritance in Man
[OMIM] #604233), severe myoclonic epilepsy (SME) and SMEI,
also known as Dravet syndrome (OMIM #607208), are
associated with mutations in the SCN1A gene (Escayg and
Goldin, 2010; Meng et al., 2015; Huang et al., 2017).
In the SCN1A mutation database (http://www.caae.org.cn/
gzneurosci/scn1adatabase/data), among 1727 mutations
described for the SCN1A gene, 1528 are related to epileptic
diseases (Table 1 and for the full description of mutations in
the SCN1A gene, see Supplementary Table S1). Among the
epilepsy-related mutations, 945 are related to severe myoclonicFrontiers in Pharmacology | www.frontiersin.org 3epilepsy of infancy (SMEI), 263 are related to severe myoclonic
epilepsy (SME), 151 are related to severe myoclonic epilepsy
borderline (SMEB), 18 are related to partial epilepsy (PE), 31 are
related to partial epilepsy and febrile seizures plus (PEFS +), 8 are
related to generalized epilepsy (GE), and 55 are related to
generalized epilepsy with febrile seizures plus (GEFS +).
Mutations in the NaV1.1 channel are described in almost all
regions of the protein and may cause GoF or LoF (Goldin and
Escayg, 2010; Meng et al., 2015). Among the 52 mutations in
SCN1A related to epilepsy with functional studies, 35 mutations
(67.30%) exclusively display characteristics of LoF, 6 mutations
(11.53%) display characteristics unique to GoF, and 11
mutations (21,15%) display characteristics of GoF+LoF,
whereas, in GoF+LoF mutations, the main characteristic that
gives GoF features is enhanced persistent current, present in 10
out of the 11 GoF+LoF mutations listed (Tables 1 and S1).
Due to the role of the NaV1.1 channels in the regulation of
electrical excitability by the inhibitory interneurons, prescription of
AEDs non-selective sodium channel blockers (SCB) for SMEI or
GEFS + syndromes is contraindicated, for it may aggravate crises
due to the enhanced suppress status of the NaV1.1 channels
(Catterall, 2014a; Shi et al., 2016; Knupp and Wirrell, 2018;
Ziobro et al., 2018). The first-line drug-based therapy for SCN1A
epilepsy diseases is the enhancement of postsynaptic GABAergic
transmission with allosteric activation of GABAA receptors as target
by Clobazam and/or an increase in GABA concentration in synaptic
cleft resulting from increased GABA production and decreased
GABA degradation as target by Valproic acid (Catterall, 2014a;
Hammer et al., 2016; Knupp and Wirrell, 2018; Musto et al., 2020).
Antisense nucleotides (ASO) therapy to increase mRNA of SCN1A
for NaV1.1 channel expression in normal levels is a promising
strategy for genetic disorders involving haploinsufficiency (Hsiao
et al., 2016; Stoke Therapeutics, 2018). Drug-resistant Dravet
syndrome cases may thrive on alternative therapeutic strategies
based on ketogenic diets (Nabbout et al., 2011; Wu et al., 2018). A
recent study with 20 patients with medically intractable Dravet
syndrome caused by missense, non-sense, insertion, deletions and
splicing mutations presents efficacy during three months of
treatment in 17 patients, decreasing seizure frequency in more
than 50% (Yan et al., 2018). Besisdes that, Epidiolex is an FDA
approved CBD-based drug approved in June 2018 for the treatment
of severe forms of epilepsy, as Dravet and Lennox-Gastaut
syndromes (U.S. Food and Drug Administration [website]., 2018).
Clinical trials using CBD in DS and LGS shown reduced frequency
of seizures in monthly average (Lattanzi et al., 2020; Morano et al.,
2020). Voltage-gated sodium channel are inhibit by CBD in low
micromolar concentrations, IC50 between 1.9 and 3.8 mM, NaV1.4
and NaV1.1 being the most sensitive channels to CBD, 1.9 and 2.0
mM respectively, probably the mechanism of action is reducing
channel availability due shift to more hyperpolarized potential in
steady-state inactivation (Ghovanloo et al., 2019).
NaV1.2
NaV1.2 is encoded by the SCN2A gene (Wolff et al., 2017). It is
located on chromosome 2q24.3 (Shi et al., 2009) and expressed in
the CNS (Catterall, 2014a), especially in excitatory neurons
(Syrbe et al., 2016) and glutamatergic neurons (Sanders et al.,August 2020 | Volume 11 | Article 1276
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A27T N-terminal Missense GEFS+
SMEB
Diffuse spikes, prevailing in posterior regions (EEG) (Nicita et al., 2010)
L61P N-terminal Missense DS Febrile seizures (Halvorsen et al., 2016)
F63L N-terminal Missense DS Severe developmental delay
Spike and Waves in right fronto-temporal region with
spreading (EEG)
(Nicita et al., 2010)
F90S N-terminal Missense DS Multifocal spikes, frontal-dominant spike-waves
complex (EEG)
(Sun et al., 2008; Wang et al., 2012; Xu et al., 2014;
Butler et al., 2017b)
S103G N-terminal Missense SME
DS
Ataxia
Rare-spike wave complex (EEG)
(Fujiwara, 2003; Ebrahimi et al., 2010; Tonekaboni
et al., 2013)
S106F N-terminal Missense Focal epilepsy Right temporal parietal occipital slow-wave and
generalized spike-wave complex (EEG)
(Barba et al., 2014)
M145T DI (S1) Missense Unidentified
epilepsy
Decrease current density
Shift steady-state inactivation to more positive values
(Mantegazza et al., 2005; Colosimo et al., 2007)
L193F DI (S3) Missense GEFS+ Generalized tonic–clonic seizures (Cui et al., 2011)
V244L DI (S4-S5) Missense DS Myoclonic seizures
Generalized spikes or spike-and-wave complexes in
the interictal (EEG)
(Morimoto et al., 2006)
R377Q DI (S5-S6) Missense GEFS+ Generalized tonic-clonic seizures (Zucca et al., 2008; Xu et al., 2015; Cetica et al.,
2017; Lindy et al., 2018)
F412I DI (S6) Missense SMEB
GEFS+
Febrile seizure (Ebrahimi et al., 2010; Tonekaboni et al., 2013)
K488EfsX6 DI-DII FrameShift DS NR (Yang et al., 2017)
R542Q DI-DII Missense GEFS+
SME
NR (Escayg et al., 2001; Weiss et al., 2003; Combi
et al., 2009; Orrico et al., 2009; Wang et al., 2012;
Lee et al., 2014; Lal et al., 2016)
R618C DI-DII Missense PEFS+ Generalized tonic-clonic seizures
Multifocal epilepsy and bilateral bursts of 3-4 Hz
spike and wave (EEG)
(Brunklaus et al., 2015)
Y790C DII (S1-S2) Missense GEFS+ Decreased current density
Decreased of cell surface expression
(Annesi et al., 2003; Orrico et al., 2009; Bechi et al.,
2015; Bennett et al., 2017)
R859H DII (S4) Missense GEFS+ Shift steady state activation and inactivation to more
negative values
Enhanced Persistent current
(Volkers et al., 2011; Myers et al., 2017a; Lindy
et al., 2018)




Paroxysmal generalised polyspike-and- wave
complexes with myoclonic seizures (EEG)
(Jingami et al., 2014)
T1174S DII-DIII Missense FHM
FS
Shift steady state activation to more positive values
Deceleration of recovery from fast inactivation
Increase of persistent current
(Escayg et al., 2001; Gargus and Tournay, 2007;
Yordanova et al., 2011; Rilstone et al., 2012; Cestèle
et al., 2013; Lal et al., 2016)
V1353L DIII (S5) Missense PEFS+
GEFS+









No definitive epileptic spikes (EEG) (Sone et al., 2012)
R1596H DIV
(S2-S3)
Missense GEFS+ Generalized spike-wave complexes (EEG)
Normal imaging (MRI)
(Hoffman-Zacharska et al., 2015)
I1656M DIV (S4) Missense GEFS+ Shift steady state activation to more positive values (Lossin et al., 2003)
G1674S DIV (S5) Missense FS+ Febrile seizure
Hemiconvulsion
(Saitoh et al., 2015a)
De novo mutation
Q3X N-terminal Nonsense DS Generalized tonic clonic seizures (Claes et al., 2003; Lim et al., 2011)
G58X N-terminal Nonsense DS
Focal Epilepsy
Autistic characteristics; Hyperactivity
Periventricular nodular heterotopia (MRI)
(Barba et al., 2014)
Y65X N-terminal Nonsense DS Generalized tonic-clonic seizures (Zucca et al., 2008)
E75D N-terminal Missense DS Slow-spike-wave complexes (EEG) (Arafat et al., 2017)
(Continued)Frontiers in Pharmacology | www.frontiersin.org 4 August 2020 | Volume 11 | Article 1276
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DS Pharmacoresistant (Usluer et al., 2016)
D81N N-terminal Missense DS Severe Motor and mental delay
Multi-focal spike-waves (EEG)
(Usluer et al., 2016)
I91T N-terminal Missense DS Frontal-dominant spike-waves complex (EEG) (Sun et al., 2008; Xu et al., 2014)
G96EfsX24 N-terminal FrameShift NR Genetic generalized epilepsy with intellectual disability (Fry et al., 2016)




Psychomotor retardation (Fukuma et al., 2004; Harkin et al., 2007; Marini
et al., 2007; Depienne et al., 2008; Sun et al., 2010;
Zuberi et al., 2011; Wang et al., 2012; Tonekaboni
et al., 2013; Lee et al., 2014; Djémié et al., 2016)
A104V N-terminal Missense DS Epileptic discharges, slow spike and weave; sharp
wave, sharp and slow wave complex (EEG)
(Kwong et al., 2012; Myers et al., 2017a)
R118S N-terminal Missense DS Generalized tonic-clonic seizures
Severe mental retardation
(Zucca et al., 2008)
F144YfsX5 DI (S1) Frameshift SME
DS
Moderate psychomotor retardation (Fukuma et al., 2004; Zuberi et al., 2011; Wang
et al., 2012; Villeneuve et al., 2014)
M145DfsX4 DI (S1) Frameshift PEFS+ Generalized tonic-clonic seizures without any
provoked factors
(Yu et al., 2010)
G177E DI (S2-S3) Missense SME
DS
Non-functional channel (Nabbout et al., 2003; Ohmori et al., 2006; Usluer
et al., 2016)
L180X DI (S2-S3) Nonsense DS Focal spike wave (EEG) (Liu et al., 2018)
W190X DI (S3) Nonsense DS Febrile, partial, generalized tonic-clonic and myo-
clonic seizures
Severe intellectual disability
(Marini et al., 2007; Kwong et al., 2012)
S213W DI (S3-S4) Missense Epilepsy Febrile and afebrile seizures
Developmental delay
(Butler et al., 2017a)
R219SfsX57 DI (S4) FrameShift DS Generalized tonic-clonic seizures (Claes et al., 2001)
R222X DI (S4) Nonsense DS
SMEB
No measurable current (Claes et al., 2001; Nabbout et al., 2003; Fukuma
et al., 2004; Harkin et al., 2007; Depienne et al.,
2008; Orrico et al., 2009; Zuberi et al., 2011; Wang
et al., 2012; Xu et al., 2014; Esterhuizen et al., 2018)
I227S DI (S4) Missense SME
SMEB
Epileptiform discharges on both sides and spikes/
polyspikes during photic stimulation (EEG)
Low current density (no detectable)
(Nabbout et al., 2003; Ohmori et al., 2006; Depienne
et al., 2008; Mak et al., 2011; Wang et al., 2012;
Lindy et al., 2018)
A239V DI (S4-S5) Missense SME
DS
Focal right fronto-temporal spikes with spreading
(EEG)
Severe developmental delay
(Iannetti et al., 2009; Nicita et al., 2010; Xu et al.,
2014)




(Nabbout et al., 2003; Wang et al., 2012; Liu et al.,
2018)
P281L DI (S5-S6) Missense DS Moderate mental retardation (Depienne et al., 2008; Gokben et al., 2017; Lindy
et al., 2018)
E311X DI (S5-S6) Nonsense DS Haploinsufficiency (Orrico et al., 2009)
G329A DI (S5-S6) Missense GEFS+ Generalized tonic–clonic seizures (Myers et al., 2017a)





(Fujiwara, 2003; Depienne et al., 2008; Zuberi et al.,
2011)
D366E DI (S5-S6) Missense DS Generalized tonic-clonic seizures (Zucca et al., 2008)





(Zuberi et al., 2011; Wang et al., 2012; Verbeek
et al., 2013)
T391P DI (S5-S6) Missense DS Generalized tonic-conic seizures
Partial Seizures
(Reyes et al., 2011)





(Claes et al., 2003; Marini et al., 2007; Sun et al.,
2010; Zuberi et al., 2011; Lemke et al., 2012;
Rilstone et al., 2012; Wang et al., 2012; Xu et al.,
2014; Djémié et al., 2016; Haginoya et al., 2018)
V422L DI (S6) Missense EE Psychomotor developmental delay
Theta activities with right predominance (EEG)
(Ohashi et al., 2014)
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Variant Location Mutation Disease Alteration on biophysical properties or/and
Clinical report
Reference
Y426N DI-DII Missense DS Decreased current density
shift stead-state inactivation to more negative values
Delayed recovery from inactivation
(Nabbout et al., 2003; Ohmori et al., 2006; Allen
et al., 2016)
L433fsX16 DI-DII FrameShift Myoclonic
astatic
epilepsy
Generalized tonic-clonic seizures (Ebach et al., 2005)
E435X DI-DII Nonsense DS Myoclonic seizures
Atypical absence
(Fukuma et al., 2004; Wang et al., 2012)
Q554H DI-DII Missense DS Generalized tonic-clonic seizure
Atonic and myoclonic seizures
(Skjei et al., 2015)
S662X DI-DII Nonsense PEFS+ Generalized tonic-clonic seizures (Yu et al., 2010)
W738X DI-DII Nonsense SME Febrile seizures
Generalized tonic-clonic
Severe intellectual disability
(Kwong et al., 2012; Xu et al., 2014)
T808S DII (S2) Missense ICEGTC Rare sharp waves in left temporal (EEG)
Increase current density
Delay recovery from inactivation
(Fujiwara, 2003; Rhodes et al., 2005)
S843X DII (S3) Nonsense DS Focal spike activity (EEG) (Buoni et al., 2006)




(Carranza Rojo et al., 2011; Barba et al., 2014)




(Claes et al., 2003; Dhamija et al., 2014)
M934I DII (S5-S6) Missense DS Moderate psychomotor retardation (Fukuma et al., 2004; Depienne et al., 2008; Wang
et al., 2012)




(Claes et al., 2003; Ohmori et al., 2006)
R946C DII (S5-S6) Missense SME
DS
SMEB
Non- functional Channel (Fukuma et al., 2004; Volkers et al., 2011; Zuberi
et al., 2011; Wang et al., 2012; Lee et al., 2014; Xu
et al., 2014; Lindy et al., 2018)





Short generalized tonic-clonic seizures at night
Seizure onset left temporo-parietal (EEG)
Seizure onset left frontal
Seizure onset right frontocentral,
(Ebach et al., 2005; Tiefes et al., 2019)
R946H DII (S5-S6) Missense PEFS+
SMEB
DS
Non-functional Channel (Fukuma et al., 2004; Harkin et al., 2007; Depienne
et al., 2008; Liao et al., 2010a; Verbeek et al., 2011;
Volkers et al., 2011; Zuberi et al., 2011; Wang et al.,
2012; Verbeek et al., 2013)




(Claes et al., 2003; Ohmori et al., 2006)
V971L DII (S6) Missense DS Generalized and unilateral tonic-clonic seizures
Myoclonic seizures
Apneic spells
(Poryo et al., 2017)
V982L DII (S6) Missense SMEB Focal epilepsy (Singh et al., 2009; Saitoh et al., 2012; Saitoh et al.,
2015a; Saitoh et al., 2015b)
V983A DII (S6) Missense ICEGTC Multifocal spikes, high voltage slow-waves (EEG)
Reduced current density
Shift steady-state inactivation to more positive values
Accelerated recovery from inactivation
(Fujiwara, 2003; Rhodes et al., 2005)
V983AfsX2 DII (S6) FrameShift DS Enlarged extracerebral gap (MRI) (Wang et al., 2017b)
L986F DII (S6) Missense DS Generalized tonic-clonic seizures
Non-functional channel
(Claes et al., 2001; Lossin et al., 2003)
L991VfsX2 DII (S6) FrameShift DS Febrile, partial, generalized tonic-clonic, myo-clonic
seizures
Moderate intellectual disability.
(Kwong et al., 2012)
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Variant Location Mutation Disease Alteration on biophysical properties or/and
Clinical report
Reference
N1011I DII-DIII Missense ICEGTC Rare sharp waves in lateral-temporal (EEG)
Reduced current density
Shift steady state inactivation to more negative values
(Fujiwara, 2003; Rhodes et al., 2005)
D1046MfsX9 DII-DIII FrameShift DS Diffuse cerebral edema (Computed tomography) (Myers et al., 2017b)
S1100KfsX8 DII-DIII FrameShift DS Generalized clonic seizures
Severe mental retardation
(Claes et al., 2001)
S1104X DII-DIII Missense DS Febrile seizures (Depienne et al., 2008; Hernández Chávez et al.,
2014)
E1153X DII-DIII Nonsense DS Focal epilepsy with frontal-lateral activity (EEG) (Hernández Chávez et al., 2014)
E1176NfsX32 DII-DIII FrameShift DS Severe intellectual disability
Intractable seizures despite multiple anti-epileptic
drugs
(Willemsen et al., 2012)
R1213X DII-DIII Nonsense SME
DS
LGS
Rare spikes, multifocal spikes and spike-wave
complex (EEG)
Severe mental delay
(Fujiwara, 2003; Depienne et al., 2008; Zuberi et al.,
2011; Wang et al., 2012; Allen et al., 2013; Xu et al.,
2014; Lindy et al., 2018)
L1230P DIII (S1) Missense DS Focal spike-wave complex (EEG)
Febrile seizures
Myoclonic seizures
(Liu et al., 2018)
F1263L DIII (S2) Missense SMEB Rare spike-wave complex and poly spike-waves
complex (EEG)
(Fujiwara, 2003)




(Harkin et al., 2007; Butler et al., 2017b)
V1637E DIV (S4) Missense DS Episodes of status epilepticus
triggered by fever
(Nishri et al., 2010; Zuberi et al., 2011)
F1671fsX8 DIV
(S4-S5)
FrameShift DS Generalized tonic-clonic seizures
Severe mental retardation
(Claes et al., 2001; Sugawara et al., 2002; Depienne
et al., 2008; Riva et al., 2009)
A1685D DIV (S5) Missense DS Spike-wave complex (EEG)
Non-functional channel
(Fujiwara, 2003) (Sugiura et al., 2012)
Y1694C DIV (S5) Missense DS Myoclonic seizures
Atypical absence
Severe psychomotor retardation




Missense SME Generalized tonic clonic seizure (Verbeek et al., 2013)
T1722A DIV
(S5-S6)
Missense DS Myoclonic, hemiclonic, focal seizures (Wu et al., 2015)
C1741S DIV
(S5-S6)
Missense TLE-MTS Febrile status epilepticus (Tiefes et al., 2019)
G1754R DIV
(S5-S6)
Missense DS Focal seizures
Hemiconvulsions
(Petrelli et al., 2012)
S1768R DIV (S6) Missense DS Absences and tonic-clonic seizures (Willemsen et al., 2012)
E1881X C-terminal Nonsense DS
SMEB
Febrile and generalized seizures (Villeneuve et al., 2014)
Non genetic origin mutations reported*
G177DfsX4 DI (S2-S3) FrameShift DS Generalized tonic-clonic seizures (Fujiwara, 2003)
V207G DI (S3) Missense EE Early-onset multifocal seizures (Daoud et al., 2016)
D249E DI (S4-S5) Missense DS Generalized tonic seizures
Absences; Mental retardation
(Le Gal et al., 2014)
N275K DI (S5) Missense PEFS+ Hippocampal volume loss (MRI) (Kim et al., 2014)
T363R DI (S5-S6) Missense DS Generalized tonic-clonic seizures (Zuberi et al., 2011; Le Gal et al., 2014)
N416I DI (S6) Missense DS Focal spike-wave (EEG) (Zhou et al., 2018)
S1631C DIV
(S3-S4)
Missense DS Multifocal spikes (EEG) (Haginoya et al., 2018)Frontiers in Pharmacology | www.frontiersin.org 7*Non genetic origin mutations reported: Mutations described through clinical diagnosis, but the mutation type (Mendelian or de novo) were not reported, mainly due to the lack of parents to
perform genotyping and difficulty in contacting the family. Generalized epilepsy with febrile seizures plus (GEFS+); Febrile seizures (FS); Febrile seizures plus (FS+); Lennox-Gastaut
syndrome (LGS); Dravet syndrome (DS); Borderline severe myoclonic epilepsy (SMEB); Severe myoclonic epilepsy (SME); Familial hemiplegic migraine (FHM); Partial epilepsy with
antecedent FS (PEFS+); Intractable childhood epilepsy with generalized tonic–clonic seizures (ICEGTC); Intractable childhood epilepsy with generalized tonic-clonic seizures (ICE-GTC);
Epileptic encephalopathy (EE); Malignant migrating partial seizures of infancy (MMPSI); Temporal lobe epilepsy (TLE); Mesial temporal sclerosis (MTS); Not Reported (NR); Domain (D);
Segment (S); Electroencephalography (EEG); Magnetic resonance imaging (MRI).August 2020 | Volume 11 | Article 1276
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the GABAergic interneurons (Catterall, 2014a).
More than 100 mutations have already been described for this
gene, with approximately 300 patients studied yet (Reynolds
et al., 2020) (Table 2). The most common diseases related with
SCN2A mutation are West syndrome (WS; OMIM #308350),
epilepsy of infancy with migrating focal seizures (EIMFS; OMIM
#616645), and benign familial neonatal-infantile seizures
(BFNIS; OMIM #607745) (Perucca and Perucca, 2019).
Although epilepsy-related mutations are present throughoutFrontiers in Pharmacology | www.frontiersin.org 8the channel, several hotspots such as the ion selectivity filter,
the voltage-sensing domain, the intracellular N-terminal, and the
C-terminal domain can be highlighted (Sanders et al., 2018).
NaV1.2 channels are expressed in the excitatory neurons;
therefore, GoF mutations are related to epilepsy because it causes
neuronal hyperexcitability. On the other hand, LoF mutations
are related to autism and intellectual disability phenotype (Ben-
Shalom et al., 2017). Nevertheless, some studies have already
related loss of function to epilepsy, as described by Lossin and co-
workers (2012) with R1312T mutation (Lossin et al., 2012).TABLE 2 | SCN2A-related epilepsies identified in clinical patients through WES and/or NGS.




R19K N-terminal Missense FS+ Febrile seizures
Partial seizure with eye deviation
(Ito et al., 2004)
R36G N-terminal Missense BFIS Focal seizures
Clonic seizures
(Wolff et al., 2017)
I172V DI (S2) Missense FS Fever-induced seizure susceptibility (Saitoh et al., 2015a)
R188W DI Missense FS+ Generalized tonic or tonic clonic seizures
Partial seizures
(Ito et al., 2004)
A202V DI Missense BFNS Focal seizures
Generalized tonic-clonic seizures
(Wolff et al., 2017)
V208E DI Missense BFIS NR (Lemke et al., 2012)
R223Q DI (S4) Missense BFNIS Positive shifts of both activation and
inactivation curves
(Berkovic et al., 2004; Scalmani
et al., 2006; Zara et al., 2013)
D322N DI
(S5-S6)







Lesions in the right parietal, temporal and
occipital lobes (MRI)
(Shi et al., 2009; Saitoh et al.,
2015a)
Q383E DI Missense BFNIS Seizures in early infancy (Syrbe et al., 2016)
E430Q DI-DII Missense BFNIS Focal spikes and bifrontal slow wave
activity (EEG)
(Herlenius et al., 2007)
A467T DI-DII Missense GEFS+ Loss of consciousness
Clonic movements of all extremities
High body temperature up to 40 ° Celsius
(Liu et al., 2018)
R524Q DI-DII Missense FS Febrile seizures (Ito et al., 2004)
V892I DII (S5) Missense BFNIS NR (Berkovic et al., 2004)
N1001K DII-DIII Missense BFIS Afebrile seizures
Tonic body extension
Right parietal–occipital sharp waves (EEG)
(Striano et al., 2006)
L1003I DII-DIII Missense BFNIS Generalized tonic-clonic seizures (Berkovic et al., 2004)
R1319Q DIII (S4) Missense
BFNIS
Shift steady state activation and inactivation
to more positive values
(Berkovic et al., 2004; Scalmani
et al., 2006; Misra et al., 2008;
Zara et al., 2013)




Missense BFNIS Shift steady state inactivation to more
positive values
(Heron et al., 2002; Scalmani
et al., 2006; Misra et al., 2008)
L1563V
DIV
Missense BFNIS Increase in neuronal excitability
Accelerated recovery from fast inactivation
(Heron et al., 2002; Scalmani
et al., 2006; Xu et al., 2007; Misra
et al., 2008; Berecki et al., 2018)
Y1589C DIV
(S2-S3)
Missense BFNIS Increased persistent Na+ current
Delayed fast inactivation
Acceleration of recovery
(Lauxmann et al., 2013)
I1596S DIV (S3) Missense BFNIS Central and posterior focal spikes (EEG) (Herlenius et al., 2007)
K1641N DIV Missense BFIS Focal seizures with secondary
generalization
(Zara et al., 2013)
(Continued)August 2020 | Volume 11 | Article 1276
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N-terminal Nonsense EE Shift steady state inactivation to more
negative values
Decrease of available channel
(Kamiya, 2004; Ogiwara et al.,
2009)
N132K DI Missense EOEE Tonic-clonic seizures (Matalon et al., 2014)
M136I DI Missense EIMFS Focal seizures
Spasms
(Carvill et al., 2013; Howell et al.,
2015)




(Nakamura et al., 2013)
W191C DI Missense EIMFS Frequent multifocal spikes (EEG) (Su et al., 2018)
F207S DI Missense BNS Tonic-clonic seizures
Clonic seizures
(Wolff et al., 2017)




Missense OS and WS Eyelid myoclonic
Spasms
Hypsarrhythmia
(Nakamura et al., 2013)
R220G DI Missense EE Generalized tonic-clonic seizures
Generalized spike and slow wave (EEG)
(Mercimek-Mahmutoglu et al.,
2015)
T227I DI Missense WS Tonic seizures
Apneic seizures
Spasms
(Wolff et al., 2017)
T236S DI (S4-S5) Missense OS Focal seizure (Nakamura et al., 2013)
A240S DI Missense EIMFS Focal seizures (Howell et al., 2015)
M252V DI (S5) Missense BFNIS Increased persistent current
Accelerated of recovery from fast
inactivation
Accelerated of recovery from slow
inactivation
(Liao et al., 2010b)
V261M DI (S5) Missense BFNIS Enhanced persistent current
Faster recovery from inactivation
(Liao et al., 2010b)





Change in slope of steady-state activation
curve
Enhanced persistent current
(Wolff et al., 2017)
E430G DI-DII Missense OS Generalized tonic-clonic seizures (Matalon et al., 2014)












(Wolff et al., 2017)
R853Q DII (S4) Missense WS Reduced transient current amplitude and




2015; Wolff et al., 2017; Berecki




EIMFS Focal seizures (Howell et al., 2015)
R856Q DII Missense OS Tonic seizures (Wolff et al., 2017)
S863F DII Missense BNS and
Focal epilepsy
Generalized tonic-clonic seizures (Wolff et al., 2017)
I873M DII Missense EIEE Abnormal electroretinogram (Trump et al., 2016)
N876T DII
(S4-S5)
Missense OS and WS Spasms
Focal seizure
(Nakamura et al., 2013)
L881P
DII Missense WS and LGS Tonic seizures
Tonic-clonic seizures
Atypical absences
(Wolff et al., 2017)
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Variant Location Mutation Disease Alteration on biophysical properties or/
and Clinical report
Reference
G882R DII Missense EIMFS Unilateral tonic-clonic (Wolff et al., 2017)
G882E





(Wolff et al., 2017)







Tonic-clonic seizures and absences
Shift steady-state activation to more
positive values
Increased slop factor
(Wolff et al., 2017)
K905N DII Missense EIMFS Focal seizures (Carvill et al., 2013; Howell et al.,
2015)









(Wolff et al., 2017)
N976K DII Missense EE Focal seizures (Howell et al., 2015)
S987I DII Missense EIEE Focal and tonic seizures (Trump et al., 2016)
G999L DII-DIII Missense Infantile
epilepsy
Diffuse slowing with high-amplitude bursts
of activity (EEG)
Generalized seizures with burst suppression
(Foster et al., 2017)
E999K DII-DIII Missense EIEE NR (Trump et al., 2016)
E999V DII-DIII Missense EIEE
OS
NR (Allen et al., 2016; Trump et al.,
2016)
I1021Y.fs*16 DII-DIII Frameshift LGS NR (Carvill et al., 2013)
E1211K
DIII (S1)
Missense WS Shift steady-state activation and inactivation
to more negative values
Slower recovery from inactivation




DIII Missense EIEE NR (Trump et al., 2016)
R1312T
DIII (S4)
Missense DS Reduced current density
Shift steady-state activation and inactivation
to more negative values
Enhanced closed-state inactivation
Slowed recovery from inactivation




Missense OS and WS Multifocal spikes (EEG) (Nakamura et al., 2013)
V1326D DIII Missense EIMFS Focal seizures (Dhamija et al., 2013)
S1336Y DIII
(S4-S5)






(Nakamura et al., 2013)
L1342P DIII Missense IOEE Progressive brain atrophy
Short tonic seizures
Multifocal sharp wave activity (EEG)
(Hackenberg et al., 2014)
I1473M DIII (S6) Missense SNEE Shift steady-state inactivation to more
negative values
(Ogiwara et al., 2009)
Q1479P DIII Missense EIEE NR (Trump et al., 2016)
V1528Cfs*7 DIII-DIV Frameshift LGS Tonic-clonic seizures
Tonic seizures
Status epilepticus
(Wolff et al., 2017)
Q1531K DIII-DIV Missense BNS Clonic seizures
Generalized tonic-clonic seizures
(Wolff et al., 2017)
I1537S and M1538I DIV Missense OS and WS Clonic seizures
Frequent seizure activity (EEG)
(Foster et al., 2017)
M1548V DIV Missense
OS and WS
Generalized tonic-clonic seizures (Wolff et al., 2017)
G1593R DIV Missense EIMFS Focal seizures (Howell et al., 2015)
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Missense EIMFS Shift steady-state activation to more
negative values
accelerated recovery from fast inactivation
(Wolff et al., 2017)
D1598G DIV (S3) Missense
SME
Severe intellectual disability
Developmental delay Seizures/ infantile
spasms





Shift steady-state inactivation to more
negative values
(Wolff et al., 2017)
T1623N DIV
(S3-S4)
Missense OS and WS Multifocal spikes (EEG)
Spasms
Hypsarrhythmia
(Nakamura et al., 2013)
V1627M DIV Missense EIMFS Focal seizures
Apnoeic seizures
(Wolff et al., 2017)
G1634V DIV Missense OS Focal seizures
Spasms
(Howell et al., 2015)
I1640S DIV Missense EE Tonic seizures
Focal seizues
(Wolff et al., 2017)




Spasms (Wolff et al., 2017)
S1656F DIV Missense LGS Generalized tonic-clonic seizures (Wolff et al., 2017)
L1660T DIV
(S4-S5)
Missense EE Generalized tonic-clonic seizures (Fukasawa et al., 2015)
L1660W DIV Missense Acute
encephalopathy
Tonic-clonic convulsions
Frequent spikes and sharp waves in the
right fronto-temporal regions (EEG)
Cerebellar atrophy (MRI)





(Wolff et al., 2017)
L1829F C-terminal Missense EIEE NR (Trump et al., 2016)
H1853R C-terminal Missense OS Generalized tonic-clonic seizures
Absence seizures
(Martin et al., 2014)
R1882L C-terminal Missense Epilepsy Generalized and irregular spike wave and
polyspike wave activity (EEG)
Focal and generalized tonic–clonic seizures
with opisthotonus, bradycardia, and
cyanosis
(Baasch et al., 2014)
R1882G C-terminal Missense BIS Shift steady-state inactivation to more
positive values
Increase current density and protein
production
(Carvill et al., 2013; Schwarz
et al., 2016; Wolff et al., 2017)
R1882Q C-terminal Missense EIEE Increased current density
Enhanced persistent current
(Trump et al., 2016; Berecki et al.,










GEFS+ Inhibits the increment of functional
expression of NaCh currents
Abolishes the shift of the voltage
dependence of activation and inactivation
(Baroni et al., 2018)
Chromosome 2q24.3

















(10.29 - 10.58 Mb)
Severe
epilepsy
Focal and generalized seizures
Stereotypic and repetitive hand movements
Slow background with high amplitude delta
waves mixed with spikes and sharp waves
on the temporo-occipital areas (EEG)
(Pescucci et al., 2007)
Non genetic origin mutations reported*
V213D DI (S4) Missense EOEE Focal seizure
Focal spikes (EEG)
(Nakamura et al., 2013)
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T218K DI Missense EIMFS Focal seizures
Spasms
(Howell et al., 2015)
D649N DI-DII Missense DS NR (Wang et al., 2012)
V752F DI-DII Missense Absence
epilepsy
Increased current density
Shift steady-state activation and inactivation
to more negative values
(Oliva et al., 2014)
M1128T DII-DIII Missense AERRPS Generalized convulsive seizure
Slow background activity and rare
multifocal spikes over the right temporal
and bilateral frontopolar regions (EEG)
Brain edema (Cranial computed
tomography)
(Kobayashi et al., 2012)
G1522A DIII-DIV Missense EE Absence seizures
Generalized spike and waves (EEG)
(Mercimek-Mahmutoglu et al.,
2015)
R1629L DIV (S4) Missense EOEE Focal seizure
Burst of spikes (EEG)
(Nakamura et al., 2013)
R1918H C-terminus Missense GEFS+ Generalized tonic-clonic seizures (Haug et al., 2001)




Epilepsy Delayed fast inactivation
Increased persistent current when
expressed in Xenopus oocytes













GEFS+ Fail to modulate fast inactivation kinetics
Fail to modulated steady-state inactivation

























GEFS+ Destabilization of steady-state inactivation
potentials
Disrupts the thermoprotective role of the b1
subunit on channel availability
(Egri et al., 2012; Abdelsayed and
Sokolov, 2013)
Chromosome 2q24.3




EOEE Multifocal spikes (EEG)
Epileptic spasms











Epileptic seizure with pale, atonic periods




(Davidsson et al., 2008)Frontiers in Pharmacology | www.frontiersin.org 12 Augus*Non genetic origin mutations reported: Mutations described through clinical diagnosis, but the mutation type (Mendelian or de novo) were not reported, mainly due to the lack of parents to
perform genotyping and difficulty in contacting the family. Generalized epilepsy with febrile seizures plus (GEFS+); Benign familial neonatal-infantile seizures (BFNIS); Benign familial neonatal
seizures (BFNS); Benign Familial Infantile Seizures (BFIS); Benign neonatal/infantile seizures (BNIS); Benign neonatal seizures (BNS); Benign infantile seizures (BIS); Febrile seizures (FS);
Febrile seizures plus (FS+); Epilepsy of infancy with migrating focal seizures (EIMFS); Ohtahara syndrome (OS); West syndrome (WS); Lennox-Gastaut syndrome (LGS); Dravet syndrome
(DS); Borderline severe myoclonic epilepsy (SMEB); Severe myoclonic epilepsy (SME); Early-onset epileptic encephalopathies (EOEE); Acute encephalitis with refractory, repetitive partial
seizures (AERRPS); Early infantile epileptic encephalopathy (EIEE); myoclonic-atonic epilepsy; Infantile onset epileptic encephalopathy (IOEE); Sporadic neonatal epileptic encephalopathy
(SNEE); Epileptic encephalopathy (EE); Not Reported (NR); Domain (D); Segment (S); Electroencephalography (EEG); Magnetic resonance imaging (MRI).t 2020 | Volume 11 | Article 1276
Menezes et al. Epilepsy-Related Nav Channelopathies: A ReviewNormally, LoF SCN2A gene mutations for epilepsy are related to
late-onset epilepsy; however, the mechanism of action is unclear
(Mason et al., 2019).
In some cases, NaV1.2 seizures are not controlled not even by
various antiepileptic drugs, as with the patient described by Syrbe
and colleagues (2016). The proband, even after being treated with
oxcarbazepine (OXC), valproic acid, topiramate, sulthiame,
phenytoin, among other drugs, kept on having seizures (Syrbe
et al., 2016). Furthermore, the SCB drugs can assist the patient
during the treatment as described by Gorman and King (2017).
The patient had seizures controlled after administration of
phenytoin (Gorman and King, 2017). In addition, Musto et al.
(2020) cite benefits treatments using SCB such as carbamazepine,
mexiletine, oxcarbazepine, phenytoin, lidocaine, and lamotrigine
for patients with early onset epilepsies (Musto et al., 2020).
Besides, Peters and colleagues studied a substance commercially
used as an antianginal drug (human heart) called ranolazine that
has been shown to affect NaV1.2 channels, reducing macroscopic
currents and delaying the recovery of fast and slow inactivation of
the NaV1.2 channel, consequently with more future studies
ranolazine could be a efficacious therapy for epilepsy (Peters
et al., 2013).
Drugs can be important to modulate channel kinetics for both
GoF and LoF, but some precautions must be observed. For
example, the degree of conservation between subtypes, such as
NaV1.2 and other sodium channels as NaV1.5 and the excessive
decrease in channel function or the excessive increase in function
obtained by the drug (Sanders et al., 2018).
Organizations like the FamilieSCN2A Foundation (www.
scn2a.org) might be essential in the search for new treatments.
Understanding the genotype-phenotype of gain and loss of
function is essential because science-patient relationship may
be helpful in the search for new therapies (Sanders et al., 2018).
NaV1.3
SCN3A is a gene that encodes for type 3 voltage-gated Na+ channel
a subunit, the NaV1.3, located on human chromosome 2q24, in a
cluster with SCN1A and SCN2A (Holland et al., 2008). NaV1.3 is
expressed predominantly in the CNS during embryonic and
neonatal development, being extremely low or sometimes
undetectable in postnatal individuals. Subsequently, during
infancy, it is gradually replaced by increased expression of the
NaV1.1 isoform (Felts et al., 1997; Whitaker et al., 2000; Cheah
et al., 2013; Zaman et al., 2018). On the other hand, studies
regarding nervous system injury and neuropathic pain showed an
increasing presence of NaV1.3 channels in affected tissues,
suggesting a pivotal hole of these transmembrane proteins in
these processes and diseases (Hains et al., 2003; Waxman and
Hains, 2006; Black et al., 2008). For the reasons mentioned above,
in the last decades, NaV1.3-associated pathogenesis has been
restricted to pain. Recently, a genetic linkage between NaV1.3
mutated variants and epilepsy has been suggested, especially in
cryptogenic epilepsy cases (OMIM#182391).
K354Q was the first described NaV1.3 epilepsy-related
mutation that revealed harmful electrophysiological alterations
(Holland et al., 2008; Estacion et al., 2010). In fact, mutations can
change many functional characteristics of NaV1.3 affectingFrontiers in Pharmacology | www.frontiersin.org 13biophysical properties differently; however, these changes result
predominantly in neuronal hyper-responsiveness (Table 3)
(Cummins and Waxman, 1997; Chen et al., 2000; Cummins
et al., 2001; Sun et al., 2007). Previous reports correlate
heterozygous variants in SCN3A in association with moderate
forms of epilepsy, while homozygosis is related with severe
cognitive damage and premature mortality, resulting in a
broad range of epileptic phenotypes (Estacion and Waxman,
2013; Vanoye et al., 2014; Lamar et al., 2017).
Different hereditary mutations on NaV1.3 have been reported
to date in patients with epilepsy. In general, the biophysical
characterization of these mutations reveals GoF, only one
mutation (N302S) is related with LoF (Chen et al., 2015), but
both GoF and LoF may lead to an increased seizure susceptibility
(Lamar et al., 2017).
Moreover, several de novo mutations in SCN3A have been
described in the last three years, related with severe infantile
neurological dysfunctions and cognitive impairments.
These mutations may alter the functionality of NaV1.3
channels, neurons organization, migration, and proliferation
during the embryonic development (Smith et al., 2018).
Epileptic encephalopathy and polymicrogyria are the main
features related with these pathogenic variants, and, so far,
polymicrogyria was not reported in other channelopathies, being
an exclusive characteristic of SCN3Amutants (Inuzuka et al., 2019).
There is a lack of clinical data on SCN3A-related epilepsies,
especially regarding treatment and the use of specific medication.
However, in vitro studies reported that mutations related with
GoF effect respond favorably to treatment using SCB, like
phenytoin, carbamazepine, lacosamide, and topiramate (Sun
et al., 2007; Sheets et al., 2008; Colombo et al., 2013; Zaman
et al., 2018). The anticonvulsant valproic acid represents a novel
and promising epigenetic therapeutic approach (Tan et al.,
2017). The compound modulates the SCN3A gene through
methylation, downregulating the expression of NaV1.3 and,
consequently, decreasing biophysical alterations in the channel.
NaV1.6
The SCN8A gene encodes for type 8 voltage-gated Na+ channel a
subunit, the NaV1.6, located in chromosome 12q13.13. The first
case of SCN8A pathogenic variant associated with epilepsy was
reported eight years ago (Veeramah et al., 2012). Thereafter, due
to advances in genome sequencing technology, especially the
WES, the number of epilepsy diagnosis associated with NaV1.6
mutations has increased significantly (OMIM #600702), with
more than 300 patients diagnosed with SCN8A epilepsy
mutations and nearly 200 different putative spots of mutations
described, totaling over 100 published reports (Table 4). A
website developed especially to present SCN8A epilepsy and
related diseases (www.scn8a.net) was created to provide
information to families, clinicians, and researchers, gathering
news and recent publications on the subject in a private forum
for family interaction, to answer questions, strengthening the ties
between the community and the researchers.
NaV1.6 is expressed since prenatal, during fetal development
(Plummer et al., 1997). Shortly after birth, expression begins to
increase, reaching maximum levels during the first years of life. ThisAugust 2020 | Volume 11 | Article 1276
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TABLE 3 | SCN3A-related epilepsies identified in clinical patients through WES and/or NGS.




K354Q DI Missense CCE Enhanced persistent current and current amplitude













R621C DI-DII Missense BECTS
FS
Centro-temporal spikes (EEG) (Zaman et al., 2018
E1111K DII-III Missense Focal
epilepsy






















GEFS+ Resistant to enter into close-state inactivation
Shift steady state inacativation to more positive
values















Facial flushing, head turning to the left, eye deviation,











Focal seizures with secondary generalization
Atonic seizures (EEG)
(Vecchi et al., 2011
De novo mutation
L247P DI Missense Childhood
focal
epilepsy
Reduced current density associated with low protein
expression
(Lamar et al., 2017)
I875T DII
(S4-S5)
Missense EE Enhanced persistente current
Shift steady-state activation and inactivation to more
negative values
Generalized convulsion, infantile spasm
(Miyatake et al.,
2018; Smith et al.,
2018; Zaman et al.,
2018)
P1333L DIII Missense EIEE Enhanced persistent current
Increased current density
Shift steady-state activation and inactivation to more
negative values
(Trujillano et al.,
2017; Zaman et al.,
2018)
M1765I DIV Missense Refractory
epilepsy
Focal and generalized seizures
Myoclonus and epileptic spasms
(Inuzuka et al.,
2019)
V1769A DIV (S6) Missense EIEE Enhanced persistent current
Shift steady-state activation to more negative values
Shift steady-state inactivation to more positive values






WS Typical hypsarrhythmic pattern (sleeping and awake) (Chong et al., 2018
Non genetic origin mutations reported*
N302S DI Missense
GEFS+
Shift steady-state activation and inactivation to more
positive values
Slower recovery from inactivation with 500 ms
duration pre pulse
Faster recovery from inactivation with 20 ms duration
pre pulse
(Chen et al., 2015)
D766N DII (S2) Missense Focal
epilepsy
Increased current amplitude by ramp voltage
protocol
(Vanoye et al.,
2014)*Non genetic origin mutations reported: Mutations described through clinical diagnosis, but the mutation type (Mendelian or de novo) were not reported, mainly due to the lack of parents to
perform genotyping and difficulty in contacting the family. Cryptogenic childhood epilepsy (CCE); Benign epilepsy with centro-temporal spikes (BECTS); Generalized epilepsy with febrile
seizures plus (GEFS+); West syndrome (WS); Febrile seizures (FS); Benign familial neonatal-infantile seizures (BFNIS); Benign familial neonatal seizures (BFNS); Dravet syndrome (DS);
Epileptic encephalopathy (EE); Early infantile epileptic encephalopathy (EIEE); Not Reported (NR); Domain (D); Segment (S); Electroencephalography (EEG).
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K101R N-terminus Missense NR (Butler et al., 2017b)
I137M D1 (S1) Missense NR (Johannesen et al., 2019)
T164M DI (S2) Missense NR (Butler et al., 2017a)
G269R DI (S5) Missense Non-functional channel (Wengert et al., 2019)
R530W DI (S6)-DII (S1) Missense NR (Olson et al., 2015)
N544 fs*39 DI (S6)-DII (S1) Frameshift NR (Johannesen et al., 2019)
S702T DI (S6)-DII (S1) Missense NR (Jang et al., 2019)
G822R DII (S3) Missense Non-functional channel (Wengert et al., 2019)
V891M DII (S5) Missense NR (Johannesen et al., 2019)
L1290V DIII (S3-S4) Missense NR (Carvill et al., 2013)
L1331V DIII (S5) Missense NR (Larsen et al., 2015)
T1360N DIII (S5-S6) Missense Shift steady-state inactivation to more negative
values
(Wengert et al., 2019)
E1442K DIII (S5-S6) Missense NR (Liu et al., 2018)
I1464T DIII (S6)-DIV (S1) Missense NR (Johannesen et al., 2019)
G1476D DIII (S6)-DIV (S1) Missense NR (Han et al., 2017)
E1483K DIII (S6)-DIV (S1) Missense NR (Gardella et al., 2016)
I1583T DIV (S3) Missense NR (Berghuis et al., 2015)
V1598A DIV (S3) Missense NR (Wang et al., 2017a)
R1638C DIV (S4) Missense Shift steady-state activation to more positive
values
(Wengert et al., 2019)
V1758A DIV (S6) Missense Shift steady-state activation to more positive
values
(Zaman et al., 2019)
N1877S C-Terminus Missense NR (Butler et al., 2017b; Johannesen et al., 2019)
R1904C C-Terminus Missense NR (Schreiber et al., 2020)
De novo mutation
Exons 2-14 – Deletion NR (Berghuis et al., 2015)
c.-8A > G UTR 5′ UTR Eight base pairs
change upstream of
start codon
NR (Johannesen et al., 2019)
c.4296A>G DIII Splice-site mutation NR (Denis et al., 2019)
M139I D1 (S1) Missense Shift steady-state inactivation to more negative
values
Enhanced persistent current
Slightly impaired fast channel inactivation
(Zaman et al., 2019)
I142V D1 (S1) Missense NR (Denis et al., 2019; Kim et al., 2019)
A205E D1 (S1) Missense NR (Lindy et al., 2018)
F210L D1 (S1) Missense NR (Mercimek-Mahmutoglu et al., 2015)
V211L DI (S3) Missense NR (Denis et al., 2019)
V211A DI (S3) Missense NR (Berkovic et al., 2018)
L213P D1 (S3) Missense NR (Denis et al., 2019)
G214D DI
(S3-S4)
Missense NR (Allen et al., 2013)
N215R DI
(S3-S4)
Missense NR (Larsen et al., 2015)
N215D DI
(S3-S4)




Missense NR (Ohba et al., 2014)
R223G D1 (S4) Missense Reduced current density
Increased current amplitude provokes by ramp
voltage protocol
(de Kovel et al., 2014; Berkovic et al., 2018;
Denis et al., 2019)
I231T D1 (S4) Missense NR (Berkovic et al., 2018)
S232P D1 (S4) Missense NR (Wang et al., 2017a)
T239S D1 (S4-S5) Missense NR (Møller et al., 2016)
I240V DI (S4-S5) Missense NR (McNally et al., 2016)
L257V DI (S5) Missense NR (Schreiber et al., 2020)
F260S DI (S5) Missense NR (Larsen et al., 2015; Boerma et al., 2016)
C261F DI (S5) Missense NR (Rim et al., 2018; Kim et al., 2019)
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L267S DI (S5) Missense NR (Malcolmson et al., 2016)
G317A DI (S5-S6) Missense NR (Denis et al., 2019)
F360A DI (S5-S6) Missense NR (Rolvien et al., 2017)
M367V DI (S5-S6) Missense NR (Lindy et al., 2018)
N374K DI (S5-S6) Missense Shift steady-state activation to more negative
values
(Johannesen et al., 2019; Zaman et al., 2019)
T386R DI (S5-S6) Missense NR (Lindy et al., 2018)
Y401H DI (S6) Missense NR (Gardella et al., 2018)
L405M DI (S6) Missense NR (Denis et al., 2019)
L407F DI (S6) Missense NR (Fung et al., 2015; Zhang et al., 2015)
A408T DI (S6) Missense NR (Trump et al., 2016; Denis et al., 2019)
V410L DI (S6) Missense NR (Larsen et al., 2015)
L483F DI (S6) –DII (S1) Missense Slight shift steady-state activation to more
negative values
(Zaman et al., 2019)
E587Ter DI (S6)-DII (S1) Nonsense NR (Schreiber et al., 2020)
I763V DII (S1) Missense NR (Butler et al., 2017b; Hewson et al., 2018;
Lindy et al., 2018; Costain et al., 2019;
Johannesen et al., 2019)
T767I DII (S1) Missense Decreased current density
Increased current amplitude provokes by voltage
ramp protocol
(Estacion et al., 2014; Gardella et al., 2018;
Lindy et al., 2018)
V791F DII (S2) Missense NR (Xie et al., 2019)
V842E DII (S4) Missense NR (Lindy et al., 2018)
S845F DII (S4) Missense NR (Lindy et al., 2018)
F846S DII (S4) Missense NR (Ohba et al., 2014)
L848W DII (S4) Missense NR (Denis et al., 2019)




(Fung et al., 2015; Zhang et al., 2015; Lindy
et al., 2018; Kim et al., 2019; Tsang et al.,
2019; Pan and Cummins, 2020; Schreiber
et al., 2020)
R850E DII (S4) Missense NR (Wang et al., 2017a)
R850L DII (S4) Missense NR (Gardella et al., 2018)
L864V DII (S4-S5) Missense NR (Gardella et al., 2018)
L875Q DII (S5) Missense NR (Allen et al., 2013)
A890T DII (S5) Missense NR (Fung et al., 2015; Larsen et al., 2015; Zhang
et al., 2015)
V891M DII (S5) Missense NR (Wang et al., 2017a)
V960D DII (S6) Missense NR (Larsen et al., 2015)
L971V DII (S6) Missense NR (Kim et al., 2019)
S978R DII (S6)-DIII (S1) Missense NR (Kim et al., 2019)
S978G DII (S6)-DIII (S1) Missense NR (Parrini et al., 2017; Gardella et al., 2018)
N984K DII (S6)-DIII (S1) Missense Shift steady-state activation to more negative
values
(Blanchard et al., 2015; Boerma et al., 2016)
G1050S DII (S6)-DIII (S1) Missense NR (McMichael et al., 2015)
S1073N DII (S6)-DIII (S1) Missense NR (Lindy et al., 2018)
E1201K DIII (S1) Missense NR (Johannesen et al., 2019)
V1274M DIII (S3) Missense NR (Jang et al., 2019)
V1315M DIII (S4-S5) Missense NR (Trump et al., 2016; Bagnasco et al., 2018;
Denis et al., 2019)
N1318S DIII
(S4-S5)
Missense NR (Johannesen et al., 2019; Lin et al., 2019)
A1319S DIII
(S4-S5)
Missense NR (Lindy et al., 2018)
A1319D DIII
(S4-S5)
Missense NR (Johannesen et al., 2019)
A1323S DIII
(S4-S5)
Missense NR (Trump et al., 2016)
A1323T DIII
(S4-S5)
Missense NR (Johannesen et al., 2019)
I1327V DIII
(S4-S5)
Missense NR (Vaher et al., 2013; Singh et al., 2015; Trump
et al., 2016)
N1329D DIII (S4-S5) Missense NR (Butler et al., 2017b)
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V1330M DIII (S4-S5) Missense NR (Schreiber et al., 2020)
L1332R DIII (S5) Missense NR (Butler et al., 2017b)
P1428_K1473del DIII (S5-S6) Missense NR (Larsen et al., 2015)
G1451S DIII (S6) Missense Non-functional channel (Blanchard et al., 2015; Denis et al., 2019)
N1466K DIII (S6)-DIV (S1) Missense NR (Ohba et al., 2014)
N1466T DIII (S6)-DIV (S1) Missense NR (Ohba et al., 2014)
Q1470K DIII (S6)-DIV (S1) Missense NR (Pons et al., 2018; Denis et al., 2019)
G1475R DIII (S6)-DIV (S1) Missense Enhanced persistent current (Hussain et al., 2016; Ortiz Madinaveitia et al.,
2017; Parrini et al., 2017; Wang et al., 2017a;
Gardella et al., 2018; Lindy et al., 2018; Xiao
et al., 2018; Kim et al., 2019; Trivisano et al.,
2019; Zaman et al., 2019; Ranza et al., 2020;
Schreiber et al., 2020)
G1476S DIII (S6)-DIV (S1) Missense NR (Lindy et al., 2018)
I1479V DIII (S6)-DIV (S1) Missense NR (Larsen et al., 2015; Lindy et al., 2018;
Schreiber et al., 2020)
E1483K DIII (S6)-DIV (S1) Missense NR (Johannesen et al., 2019)
A1491V DIII (S6)-DIV (S1) Missense Shift steady-state activation to more negative
values
Increased current amplitude provokes by slow
voltage ramp protocol
(Gardella et al., 2018; Lindy et al., 2018;
Zaman et al., 2019)
M1494T DIII (S6)-DIV (S1) Missense NR (Kim et al., 2019)
K1498M DIII (S6)-DIV (S1) Missense NR (Gardella et al., 2018)
M1529V DIV (S1) Missense NR (Johannesen et al., 2019)
I1532F DIV (S1) Missense NR (Møller et al., 2016; Gardella et al., 2018)
M1536I DIV (S1) Missense NR (Lindy et al., 2018)
F1547V DIV
(S1-S2)
Missense NR (Gardella et al., 2018)
F1588L DIV (S3) Missense NR (Johannesen et al., 2019)
V1592L DIV (S3) Missense NR (Larsen et al., 2015; Ranza et al., 2020)




Missense NR (Larsen et al., 2015)
T1614A DIV
(S3-S4)
Missense NR (Johannesen et al., 2019)
R1617Q DIV (S4) Missense Increased persistent current
Increased peak current density
Shift steady state activation to more negative
values
Shift steady-state inactivation to more positive
values
(Rauch et al., 2012; Ohba et al., 2014;
Dyment et al., 2015; Fung et al., 2015; Larsen
et al., 2015; Zhang et al., 2015; Fung et al.,
2017; Lindy et al., 2018; Johannesen et al.,
2019; Schreiber et al., 2020)
R1620L DIV (S4) Missense NR (Rossi et al., 2017)
L1621W DIV (S4) Missense NR (Fung et al., 2015)
G1625R DIV (S4) Missense NR (Deciphering Developmental Disorders Study,
2015)
L1630P DIV (S4) Missense NR (Schreiber et al., 2020)
I1631N DIV (S4) Missense NR (Lindy et al., 2018)
M1645I DIV
(S4-S5)
Missense NR (Zhang et al., 2015)
A1650T DIV
(S4-S5)
Missense NR (Ohba et al., 2014; Larsen et al., 2015; Parrini




Missense NR (Lindy et al., 2018; Johannesen et al., 2019)
F1754S DIV (S6) Missense NR (Trump et al., 2016)
V1758A DIV (S6) Missense Shift steady-state activation to more positive
values
(Balciuniene et al., 2019; Johannesen et al.,
2019; Zaman et al., 2019)
N1759T DIV (S6) Missense NR (Kim et al., 2019)
A1763G DIV (S6) Missense NR (Denis et al., 2019)
I1764M DIV (S6) Missense NR (Gardella et al., 2018)
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(Veeramah et al., 2012)
V1771I C-Terminus Missense NR (Johannesen et al., 2019)
Q1801E C-Terminus Missense NR (Larsen et al., 2015)
R1820X C-Terminus Nonsense NR (Møller et al., 2016; Johannesen et al., 2019)
R1831Q C-Terminus Missense NR (Liu et al., 2018)
R1831W C-Terminus Missense NR (Jang et al., 2019)
T1852I C-Terminus Missense NR (Lindy et al., 2018; Heyne et al., 2019)
L1865P C-Terminus Missense NR (Trump et al., 2016)
R1866Q C-Terminus Missense NR (Kothur et al., 2018; Johannesen et al., 2019)
E1870D C-Terminus Missense NR (Boerma et al., 2016)
R1872L C-Terminus Missense Enhanced persistent current
Increased peak current density
Shift steady-state activation to more negative
values
Shift steady-state inactivation to more positive
values
(Wagnon et al., 2016; Sprissler et al., 2017;
Lindy et al., 2018; Zaman et al., 2019;
Schreiber et al., 2020)
R1872Q C-Terminus Missense Enhanced persistent current
Increase peak current density
Shift steady-state activation to more negative
values
Shift steady-state inactivation to more positive
values
(Larsen et al., 2015; Horvath et al., 2016;
Hussain et al., 2016; Arafat et al., 2017;
Atanasoska et al., 2018; Lindy et al., 2018)
R1872W C-Terminus Missense Enhanced persistent current
Increased peak current density
Shift steady-state activation to more negative
values
Shift steady-state inactivation to more positive values
(Ohba et al., 2014; Larsen et al., 2015;
Takahashi et al., 2015; Gardella et al., 2018;
Denis et al., 2019; Kim et al., 2019; Zaman
et al., 2019)
N1877S C-Terminus Missense NR (Anand et al., 2016; Parrini et al., 2017; Wang
et al., 2017a; Lindy et al., 2018; Costain et al.,
2019; Epifanio et al., 2019; Jain et al., 2019;
Ranza et al., 2020)
P1878S C-Terminus Missense NR (Lindy et al., 2018)
Non genetic origin mutations reported*
R45Q N-terminus Missense NR (Encinas et al., 2019; Heyne et al., 2019)
A108fsXTer7 N-terminus Truncated gene NR (Encinas et al., 2019)
T166I DI (S2) Missense NR (Encinas et al., 2019)
I202N DI (S3) Missense NR (Butler et al., 2017a)
V211L DI (S3) Missense NR (Encinas et al., 2019)
V211A DI (S3) Missense NR (Encinas et al., 2019)
R220H D1 (S4) Missense NR (Oates et al., 2018)
R223S DI (S4) Missense NR (Encinas et al., 2019)
T239A DI (S4-S5) Missense NR (Encinas et al., 2019)
I240V DI (S4-S5) Missense NR (Encinas et al., 2019)
I240L DI (S4-S5) Missense NR (Encinas et al., 2019)
L257V DI (S5) Missense NR (Encinas et al., 2019)
L267V DI (S5) Missense NR (Denis et al., 2019)
I268L DI (S5) Missense NR (Encinas et al., 2019)
F360A DI (S5-S6) Missense NR (Encinas et al., 2019)
M367V DI (S5-S6) Missense NR (Encinas et al., 2019)
R381Q DI (S5-S6) Missense NR (Encinas et al., 2019)
T386R DI (S5-S6) Missense NR (Encinas et al., 2019; Schreiber et al., 2020)
S399P DI (S6) Missense NR (Encinas et al., 2019; Heyne et al., 2019)
V410L DI (S6) Missense NR (Encinas et al., 2019)
Y414F DI (S6)-DII (S1) Missense NR (Butler et al., 2017a)
E416K DI (S6)-DII (S1) Missense NR (Encinas et al., 2019)
Q417P DI (S6)-DII (S1) Missense NR (Encinas et al., 2019)
R530Q DI (S6)-DII (S1) Missense NR (Encinas et al., 2019)
E587Ter DI (S6)-DII (S1) Nonsense NR (Encinas et al., 2019)
(Continued)Frontiers in Pharmacology | www.frontiersin.org 18 August 2020 | Volume 11 | Article 1276
Menezes et al. Epilepsy-Related Nav Channelopathies: A ReviewTABLE 4 | Continued
Variant Location Mutation Alteration on biophysical properties or/and
Clinical report
Reference
R598W DI (S6)-DII (S1) Missense NR (Encinas et al., 2019)
G692R DI (S6)-DII (S1) Missense NR (Encinas et al., 2019)
I763V DII (S1) Missense NR (Butler et al., 2017a; Encinas et al., 2019)
T767I DII (S1) Missense Shift steady-state activation to more negative
values
(Estacion et al., 2014)
L840P DII (S3-S4) Missense NR (Encinas et al., 2019)
L840F DII (S3-S4) Missense NR (Encinas et al., 2019)
S845F DII (S4) Missense NR (Encinas et al., 2019)
L864V DII (S4-S5) Missense NR (Trivisano et al., 2019)
l868T DII (S4-S5) Missense NR (Encinas et al., 2019)
A874T DII (S4-S5) Missense NR (Encinas et al., 2019)
V881A DII (S5) Missense NR (Encinas et al., 2019)
E936K DII (S6) Missense NR (Johannesen et al., 2019)
L969M DII (S6) Missense NR (Encinas et al., 2019)
S979F DII (S6)-DIII (S1) Missense NR (Encinas et al., 2019)
G1050S DII (S6)-DIII (S1) Missense NR (Encinas et al., 2019)
Y1241C DIII (S2) Missense NR (Encinas et al., 2019; Johannesen et al., 2019)
S1308P DIII (S4) Missense NR (Encinas et al., 2019)
V1315M DIII
(S4-S5)
Missense NR (Encinas et al., 2019)
L1320F DIII (S4-S5) Missense NR (Encinas et al., 2019; Schreiber et al., 2020)
A1323P DIII
(S4-S5)
Missense NR (Encinas et al., 2019)
I1327V DIII
(S4-S5)
Missense NR (Oates et al., 2018)
M1328T DIII
(S4-S5)
Missense NR (Encinas et al., 2019)
N1329D DIII
(S4-S5)
Missense NR (Butler et al., 2017a)
G1451S DIII (S6) Missense NR (Encinas et al., 2019)
G1461V DIII (S6) Missense NR (Encinas et al., 2019; Schreiber et al., 2020)
N1466K DIII (S6)-DIV (S1) Missense NR (Encinas et al., 2019)
F1467C DIII (S6)-DIV (S1) Missense NR (Encinas et al., 2019)
Q1470H DIII (S6)-DIV (S1) Missense NR (Trivisano et al., 2019)
I1479V DIII (S6)-DIV (S1) Missense NR (Encinas et al., 2019)
A1491V DIII (S6)-DIV (S1) Missense Shift steady-state activation to more negative
values
(Johannesen et al., 2018; Trivisano et al.,
2019)
M1492V DIII (S6)-DIV (S1) Missense NR (Encinas et al., 2019; Ranza et al., 2020)
Q1501K DIII (S6)-DIV (S1) Missense NR (Encinas et al., 2019)
Splice donor
c.4419+1A>G
DIII (S6)-DIV (S1) Truncated gene NR (Encinas et al., 2019)
M1536I DIV (S1) Missense NR (Encinas et al., 2019)
V1592L DIV (S3) Missense NR (Encinas et al., 2019)
I1594L DIV (S3) Missense NR (Encinas et al., 2019)
S1596C DIV (S3) Missense NR (Encinas et al., 2019)
T1614A DIV
(S3-S4)
Missense NR (Encinas et al., 2019)
R1617Q DIV (S4) Missense Enhanced persistent current
Increased peak current density
Shift steady-state activation to more negative
values
Shift steady-state inactivation to more positive
values
(Encinas et al., 2019)
R1617P DIV (S4) Missense NR (Encinas et al., 2019)
G1625R DIV (S4) Missense NR (Encinas et al., 2019)
L1630P DIV (S4) Missense NR (Encinas et al., 2019)
F1642C DIV
(S4-S5)
Missense NR (Encinas et al., 2019)
A1650T DIV
(S4-S5)
Missense NR (Trivisano et al., 2019)
A1650V DIV
(S4-S5)
Missense NR (Encinas et al., 2019)
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Menezes et al. Epilepsy-Related Nav Channelopathies: A Reviewchannel is widely expressed in the nodes of Ranvier of myelinated
axons and in the distal part of the axon initial segments (AIS),
although they are also ubiquitously present throughout the central
and peripheral nervous systems, in both excitatory and inhibitory
neurons (Caldwell et al., 2000; Oliva et al., 2012). For these reasons,
NaV1.6 is one of the most common subtype of voltage-gated
sodium channels found in the central nervous system (Caldwell
et al., 2000). In humans, the distal AIS is the specialized membrane
region in neurons where action potentials are triggered.
Overexpression of Nav1.6 in the AIS has been shown to cause an
increase in spontaneous and repetitive firing (Hu et al., 2009; Sun
et al., 2013), a possible explanation for why SCN8A mutations in
epilepsy patients are predominantly GoF and affect the action
potential threshold. On the other hand, the functional importance
of Nav1.6 in inhibitory interneurons is not clear yet, but evidence
indicates a role for Nav1.6 in establishing synaptic inhibition in the
thalamic network (Makinson et al., 2017), supporting the LoF
results caused by missense mutations in the mature protein.
These attributes lead to different network effects in distinct
nervous system circuits. Mutations in SCN8A are associated with
early-infantile epileptic encephalopathy type 13 (EIEE13; OMIM
#614558), a phenotypically heterogeneous early onset epilepsy, with
seizure onset happening before 18 months of age (Hammer et al.,
2016). Patients typically develop intellectual disability,
developmental delay, and movement disorders (Ohba et al., 2014;
Gardella et al., 2016; Johannesen et al., 2018). Co-occurrence of
autism spectrum disorders, severe juvenile osteoporosis,
bradyarrhythmia, cortical visual impairment, and gastrointestinal
disorders have been reported in rare cases (Larsen et al., 2015;
Hammer et al., 2016; Rolvien et al., 2017; Gardella et al., 2018).Frontiers in Pharmacology | www.frontiersin.org 20Sudden unexpected death in epilepsy (SUDEP) has also been linked
to SCN8Amutations, described as the most common cause of death
in epilepsy patients. Reports have suggested that patients with
SCN8A-related epilepsy have increased risk of SUDEP, ranging
from 1% to 10% (Hammer et al., 2016; Wang et al., 2017a; Gardella
et al., 2018; Johannesen et al., 2018). One possible correlation of
SUDEP with SCN8A-related epilepsy is the presence of NaV1.6 in
heart muscles and tissues, being broadly expressed within
ventricular myocytes (Maier et al., 2002). Single mutations may
affect heart function, causing failure of the cardiorespiratory system
and, consequently, death (Haufe et al., 2005; Noujaim et al., 2012).
Most recently, few cases of SCN8A-related epilepsies with “milder”
phenotype were associated with benign familial infantile seizures-5
(BFIS5; OMIM #617080) (Anand et al., 2016; Gardella et al., 2016;
Han et al., 2017).
An increase in new described variants made some mutation
patterns visible. Wagnon and co-workers observed numerous cases
of the same epiletogenic mutation, and suggested that CpG
dinucleotides are mutation hotspots that, through enzymatic
processing and epigenetic methylation, can convert cytosine to
thymine, such as arginine residues 1617 and 1872 (Wagnon and
Meisler, 2015). The prominent number of new variant cases in
Arg850 indicates this residue as a new hotspot, since the arginine
codon holds a CpG dinucleotide. In addition to these mutation
hotspots, residues I763, I1327, G1475, A1650, and N1877 do not
present CpG dinucleotides in their codon; however, they can be
considered recurrent mutations in view of its high repetition cases in
literature (Table 4).
The mutation at position c.- 8A>G produces a pathogenic
variant, despite not being inside the gene, or promoter regions,TABLE 4 | Continued





Missense NR (Johannesen et al., 2019)
N1759S DIV (S6) Missense NR (Encinas et al., 2019; Schreiber et al., 2020)
M1760I DIV (S6) Missense Shift steady-state activation to more negative
values
Increase action potential firing frequency
(Liu et al., 2019)
N1768D C-Terminus Missense Increased spontaneous firingParoxysmal
depolarizing shift like complexes
Increased firing frequency
Enhanced persistent current
(Veeramah et al., 2012; Encinas et al., 2019)
K1807N C-Terminus Missense NR (Encinas et al., 2019)
R1831W C-Terminus Missense NR (Encinas et al., 2019)
D1833H C-Terminus Missense NR (Johannesen et al., 2019)
T1852I C-Terminus Missense NR (Encinas et al., 2019; Ranza et al., 2020)
R1872L C-Terminus Missense Increased persistent current
Increased peak current density
Shift steady state activation to more negative
values
Shift steady inactivation to more positive values
(Encinas et al., 2019)
N1877S C-Terminus Missense NR (Johannesen et al., 2019; Schreiber et al.,
2020)
R1904C C-Terminus Missense NR (Encinas et al., 2019)*Non genetic origin mutations reported: Mutations described through clinical diagnosis, but the mutation type (Mendelian or de novo) were not reported, mainly due to the lack of parents to
perform genotyping and difficulty in contacting the family. Not Reported (NR); Domain (D); Segment (S).August 2020 | Volume 11 | Article 1276
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in an untranslated region outside of the Kozak consensus sequence
(Johannesen et al., 2019). Its role in SCN8A-related epilepsy is still
unclear; however, it may change RNA stability, modulate
transcriptional factors and promoters, modify the initiation of
translation, or work as an enhancer or silencer in the splicing
pattern. For all the reasons mentioned above, Nav1.6 variants are
predominantly harmful, and the same mutation can lead to
different phenotypes, hampering the correlation of genotypes with
phenotypes (Blanchard et al., 2015).
SCN8Amutations can be both GoF and LoF, which will likely
require different approaches and targets. Even in patients with
the same SCN8A mutation, the response to the same drug
treatment can differ. Surprisingly, most SCN8A-related
epilepsies respond favorably to channel blockers. Phenytoin
and lacosamide are SBCs widely used in SCN8A mutations
with GoF effect, while carbamazepine exhibited positive seizure
control in a patient with NaV 1.6 mutation and LoF effect.
(Blanchard et al., 2015; Wagnon and Meisler, 2015; Hammer
et al., 2016; Perucca and Perucca, 2019). Phenytoin demonstrated
effectiveness in decreasing seizure episodes in several patients with
SCN8A-related epilepsies, however, side effects during prolonged
use are very common (Boerma et al., 2016; Braakman et al., 2017). A
recent study of a DS model using zebrafish demonstrated the use of
the channel blocking compound MV1312, which is 5–6 fold
selectivity of NaV1.6 over NaV1.1–1.7, reduced burst movement
phenotype and the number of epileptiform events, activity similar to
that described with the use of a selective NaV1.1 activator AA43279
(Weuring et al., 2020). Selective Nav1.6 blockers may represent a
new therapeutic strategy for DS patients. In addition, two precise
and promising drugs have been described recently: XEN901 and
GS967. XEN901 is an arylsulfonamide highly selective and potent
NaV1.6 inhibitor that binds specifically in voltage sensor domain
IV, avoiding recovery from inactivation. GS967 is a NaV1.6
modulator that inhibits the persistent sodium current and exhibits
a protective effect (Baker et al., 2018; Bialer et al., 2018).
NaV1.7
The SCN9A gene encodes for the NaV1.7 channel, located in
chromosome 2q24 (Yang et al., 2018). NaV1.7 is expressed
preferably in the PNS, but it is also expressed in the CNS (Cen
et al., 2017). Consequently, mutations in this channel are
generally related to pain disorders (Young, 2007; Han et al.,
2009; Doty, 2010; Rush et al., 2018); however, current studies
have described a correlation between epilepsy and this channel
(OMIM #603415).
Pain disorder mutations with GoF are related with diseases such
as erythromelalgia (EMI), small-fiber neuropathy (SFN) and
paroxysmal extreme pain disorder (PEPD), and mutations with
LoF are related with congenital insensitivity to pain (CIP) (Cen
et al., 2017). Epilepsy studies such as Zhang S. et al. (2020) showed
mutations with GoF phenotype: W1150R, N641Y, and K655R
mutations (Table 5). Being that, after treatment with OXC (120
µmol/L), N641Y and K655R reduced sodium current and decreased
the opening time of the channel, while W1150R did not alter that
(Zhang S. et al., 2020). However, in a study conducted by Yang et al.
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Menezes et al. Epilepsy-Related Nav Channelopathies: A Reviewseizure with fever, treated with sodium valproic acid, and a LoF
mutation I1901fs was observed (Yang et al., 2018) (Table 5).
Variants of NaV1.7 have been related with febrile seizure or
GEFS+ (Cen et al., 2017; Zhang S. et al., 2020) and even as
asymptomatic (Singh et al., 2009). However, SCN9A can act as a
putative modifier of NaV1.1 gene; consequently, it can elevate
the severity of patients’ phenotype (Guerrini et al., 2010; Parihar
and Ganesh, 2013). Some NaV1.7 mutations could probably
contribute to generate a genetic susceptibility to a known
epilepsy disease called Dravet syndrome, in a multifactorial
way, as a modifier gene (Singh et al., 2009; Doty, 2010; Mulley
et al., 2013; Cen et al., 2017; Zhang T. et al., 2020). That said,
some rare cases of DS found in patients can be understood
(Mulley et al., 2013). For example, even parents with mild
phenotype had children with severe cases (Guerrini et al., 2010).CONCLUSION AND FUTURE
PERSPECTIVES
The past two decades have enabled remarkable progress in
understanding monogenic epilepsies. NaV-related epilepsies are
diseases of phenotypic heterogeneity, since sodium channels are
found in both the CNS and the PNS, but with different expression
ranges. The lack of a clear genotype-phenotype correlation to help
guide patient counseling and management by healthcare
professionals makes it very complex, and often expensive, to
determine a correct diagnosis. Consequently, identify the
monogenic mutation in individual patients with epilepsy is
important not only for diagnosis and prognosis, but also for a
correct treatment approach (Mei et al., 2017; Reif et al., 2017).
Susceptibility to specific treatments may be different depending
on the disease’s features, diverging even in patients who share the
same phenotype and/or mutation (Weber et al., 2014). The use of
innovative tools that facilitate and prevent diagnostic delay in
patients with epilepsy of unknown etiology onset is crucial. WES
has proved to be a valuable tool to circumvent the lack of an
accurate and fast diagnosis to epilepsies caused by monogenic
mutation, and also cheapen and drastically anticipate diagnosis.
This genetic diagnostic tool may reduce traditional investigation
costs by 55 to 70%, besides avoiding further pre-surgical evaluation
and epilepsy surgery (Kothur et al., 2018; Oates et al., 2018). In
addition to the financial impact, it can anticipate diagnosis from
nearly 3.5 years to 21 days, optimizing management and health care
support (Oates et al., 2018).
Effective and safe drugs for the treatment of monogenic
epilepsy are still an unmet clinical need. The drugs currently
available in the pharmaceutical market are only palliative
methods for a temporary control of the disease symptoms, and
few patients will benefit from the existing pharmacotherapy,
since a great number of patients treated with antiepileptic
channel blockers showed no improvement in clinical
conditions. Also, most treated patients exhibited manifold side
effects, and the prolonged use of these medications proved to be
harmful (Boerma et al., 2016; Braakman et al., 2017). Several
examples of novel and promising candidate compounds to beFrontiers in Pharmacology | www.frontiersin.org 22used in personalized medicine, such as precision therapies, have
been suggested. A previously study demonstrated that CBD at
1mM inhibit preferably resurgent currents than transient current
in Nav1.6 WT and also inhibit peak resurgent current in Nav1.6
mutant N1768D, with less effect in current density and without
alters voltage dependence of activation (Patel et al., 2016)
Possibly the modulation of CBD over mutations in SCN8A
that promotes a phenotype with increased resurgent currents
would cause a reduction in the causative excitability of epileptic
seizures. CBD also showed its ability to preferential inhibit
resurgent currents in the NaV1.2 channel (Mason and
Cummins, 2020). Due the role of Nav1.2 and Nav1.6 in
excitatory neurons, preferentially inhibition in resurgent
currents by CBD could possibly reduce the excitability in that
subset of neurons and decrease the frequency of seizures by a
change in threshold of activation and repetitive fire (Lewis and
Raman, 2014). Peptides derived from scorpion and spider venom
are well known modulator tools in neuroscience and showed
specific capacity to regulate most NaV subtypes related with
monogenic epilepsy, unlike the available promiscuous drugs that
generally interact with any NaV channel isoform (Schiavon et al.,
2006; Israel et al., 2018; Richards et al., 2018; Tibery et al., 2019;
Zhang et al., 2019). Bioengineering tools, like antisense
oligonucleotides capable to regulate NaV1.1 channels expression,
and the peptide Hm1, that modulates the function of this subtype
of sodium channel, are some innovative treatment examples
(Richards et al., 2018; Stoke Therapeutics, 2018).
However, there is still a long path toward the development of
efficacious treatments for NaV-related epilepsies. Recent studies
offered a better understanding of the complexity of the phenotypic
and genetic spectrum, which has only just begun to be elucidated.
Biomolecular diagnostic tools will drastically reduce the
developmental and cognitive effects caused by misdiagnosis and
late diagnosis, and maybe, in the upcoming years, the treatment for
inherited NaV-related epilepsies will be conducted ideally in utero,
during the prenatal stage. Moreover, further functional studies, with
greater cohorts of patients, represent an urgent medical need for a
better understanding of the correlations between genotype and
clinical symptoms, as well as the different NaV-related epilepsies
mechanisms. These studies will improve clinical efficacy and
promote safety diagnostic strategies, as well as develop prognosis
prediction in the near future.AUTHOR CONTRIBUTIONS
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Dyment, D. A., Tétreault, M., Beaulieu, C. L., Hartley, T., Ferreira, P., Chardon, J. W.,
et al. (2015). Whole-exome sequencing broadens the phenotypic spectrum of rare
pediatric epilepsy: A retrospective study. Clin. Genet. 88, 34–40. doi: 10.1111/
cge.12464
Ebach, K., Joos, H., Doose, H., Stephani, U., Kurlemann, G., Fiedler, B., et al.
(2005). SCN1A mutation analysis in myoclonic astatic epilepsy and severe
idiopathic generalized epilepsy of infancy with generalized tonic-clonic
seizures. Neuropediatrics 36, 210–213. doi: 10.1055/s-2005-865607
Ebrahimi, A., Houshmand, M., Tonekaboni, S. H., Fallah Mahboob Passand, M. S.,
Zainali, S., and Moghadasi, M. (2010). Two Novel Mutations in SCN1A Gene
in Iranian Patients with Epilepsy. Arch. Med. Res. 41, 207–214. doi: 10.1016/
j.arcmed.2010.04.007
Egri, C., Vilin, Y. Y., and Ruben, P. C. (2012). A thermoprotective role of the
sodium channel b 1 subunit is lost with the b 1(C121W) mutation. Epilepsia 53,
494–505. doi: 10.1111/j.1528-1167.2011.03389.x
Encinas, A. C., Moore, I., (Ki), M., Watkins, J. C., and Hammer, M. F. (2019).
Influence of age at seizure onset on the acquisition of neurodevelopmental
skills in an SCN8A cohort. Epilepsia 60, 1711–1720. doi: 10.1111/epi.16288
Epifanio, R., Zanotta, N., Giorda, R., Bardoni, A., and Zucca, C. (2019). Novel
epilepsy phenotype associated to a known SCN8Amutation. Seizure 67, 15–17.
doi: 10.1016/j.seizure.2019.01.017
Escayg, A., Heils, A., MacDonald, B. T., Haug, K., Sander, T., and Meisler, M. H.
(2001). A Novel SCN1A Mutation Associated with Generalized Epilepsy with
Febrile Seizures Plus—and Prevalence of Variants in Patients with Epilepsy.
Am. J. Hum. Genet. 68, 866–873. doi: 10.1086/319524
Escayg, A., and Goldin, A. L. (2010). Sodium channel SCN1A and epilepsy :
Mutations and mechanisms. Epilepsia 51, 1650–1658. doi: 10.1111/j.1528-
1167.2010.02640.x
Estacion, M., Gasser, A., Dib-Hajj, S. D., and Waxman, S. G. (2010). A sodium
channel mutation linked to epilepsy increases ramp and persistent current of
Nav1.3 and induces hyperexcitability in hippocampal neurons. Exp. Neurol.
224, 362–368. doi: 10.1016/j.expneurol.2010.04.012
Estacion, M., and Waxman, S. G. (2013). The response of NaV1.3 sodium
channels to ramp stimuli: Multiple components and mechanisms.
J. Neurophysiol. 109, 306–314. doi: 10.1152/jn.00438.2012
Estacion, M., O’Brien, J. E., Conravey, A., Hammer, M. F., Waxman, S. G., Dib-
Hajj, S. D., et al. (2014). A novel de novo mutation of SCN8A (Nav1.6) with
enhanced channel activation in a child with epileptic encephalopathy.
Neurobiol. Dis. 69, 117–123. doi: 10.1016/j.nbd.2014.05.017
Esterhuizen, A.II, Mefford, H. C., Ramesar, R. S., Wang, S., Carvill, G. L., and
Wilmshurst, J. M. (2018). Dravet syndrome in South African infants: Tools for
an early diagnosis. Seizure 62, 99–105. doi: 10.1016/j.seizure.2018.09.010
Falco-Walter, J. J., Scheffer, I. E., and Fisher, R. S. (2018). The new definition and
classification of seizures and epilepsy. Epilepsy Res. 139, 73–79. doi: 10.1016/
j.eplepsyres.2017.11.015
Felts, P. A., Yokoyama, S., Dib-Hajj, S., Black, J. A., and Waxman, S. G. (1997).
Sodium channel a-subunit mRNAs I, II, III, NaG, Na6 and hNE (PN1):
different expression patterns in developing rat nervous system.Mol. Brain Res.
45, 71–82. doi: 10.1016/S0169-328X(96)00241-0
Fisher, R. S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J. H., Elger, C. E.,
et al. (2014). ILAE Official Report: A practical clinical definition of epilepsy.
Epilepsia 55, 475–482. doi: 10.1111/epi.12550
Foster, L. A., Johnson, M. R., MacDonald, J. T., Karachunski, P.II, Henry, T. R.,
Nascene, D. R., et al. (2017). Infantile Epileptic Encephalopathy Associated
With SCN2A Mutation Responsive to Oral Mexiletine. Pediatr. Neurol. 66,
108–111. doi: 10.1016/j.pediatrneurol.2016.10.008Frontiers in Pharmacology | www.frontiersin.org 25Fry, A. E., Rees, E., Thompson, R., Mantripragada, K., Blake, P., Jones, G., et al.
(2016). Pathogenic copy number variants and SCN1A mutations in patients
with intellectual disability and childhood-onset epilepsy. BMC Med. Genet. 17,
34. doi: 10.1186/s12881-016-0294-2
Fujiwara, T. (2003). Mutations of sodium channel alpha subunit type 1 (SCN1A)
in intractable childhood epilepsies with frequent generalized tonic-clonic
seizures. Brain 126, 531–546. doi: 10.1093/brain/awg053
Fukasawa, T., Kubota, T., Negoro, T., Saitoh, M., Mizuguchi, M., Ihara, Y., et al.
(2015). A case of recurrent encephalopathy with SCN2A missense mutation.
Brain Dev. 37, 631–634. doi: 10.1016/j.braindev.2014.10.001
Fukuma, G., Oguni, H., Shirasaka, Y., Watanabe, K., Miyajima, T., Yasumoto, S.,
et al. (2004). Mutations of Neuronal Voltage-gated Na+ Channel alpha1
Subunit Gene SCN1A in Core Severe Myoclonic Epilepsy in Infancy (SMEI)
and in Borderline SMEI (SMEB). Epilepsia 45, 140–148. doi: 10.1111/j.0013-
9580.2004.15103.x
Fung, L.-W. E., Kwok, S.-L. J., and Tsui, K.-W. S. (2015). SCN8A mutations in
Chinese children with early onset epilepsy and intellectual disability. Epilepsia
56, 1319–1320. doi: 10.1111/epi.12925
Fung, C. W., Kwong, A. K. Y., and Wong, V. C. N. (2017). Gene panel analysis for
nonsyndromic cryptogenic neonatal/infantile epileptic encephalopathy.
Epilepsia Open 2, 236–243. doi: 10.1002/epi4.12055
Gamal El-Din, T. M., Martinez, G. Q., Payandeh, J., Scheuer, T., and Catterall, W. A.
(2013). A gating charge interaction required for late slow inactivation of the
bacterial sodium channel NavAb. J. Gen. Physiol. 142, 181–190. doi: 10.1085/
jgp.201311012
Gardella, E., Becker, F., Møller, R. S., Schubert, J., Lemke, J. R., Larsen, L. H. G., et al.
(2016). Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A
mutation. Ann. Neurol. 79, 428–436. doi: 10.1002/ana.24580
Gardella, E., Marini, C., Trivisano, M., Fitzgerald, M. P., Alber, M., Howell, K. B.,
et al. (2018). The phenotype of SCN8A developmental and epileptic
encephalopathy. Neurology 91, E1112–E1124. doi: 10.1212/WNL.00000000
00006199
Gargus, J. J., and Tournay, A. (2007). Novel Mutation Confirms Seizure Locus
SCN1A is Also Familial Hemiplegic Migraine Locus FHM3. Pediatr. Neurol.
37, 407–410. doi: 10.1016/j.pediatrneurol.2007.06.016
Ghovanloo, M. R., Aimar, K., Ghadiry-Tavi, R., Yu, A., and Ruben, P. C. (2016).
Physiology and Pathophysiology of Sodium Channel Inactivation. Curr. Top.
Membr. 78, 479–509. doi: 10.1016/bs.ctm.2016.04.001
Gokben, S., Onay, H., Yilmaz, S., Atik, T., Serdaroglu, G., Tekin, H., et al. (2017).
Targeted next generation sequencing: the diagnostic value in early-onset
epileptic encephalopathy. Acta Neurol. Belg. 117, 131–138. doi: 10.1007/
s13760-016-0709-z
Gilchrist, J., Das, S., Van Petegem, F., and Bosmans, F. (2013). Crystallographic
insights into sodium-channel modulation by the b4 subunit. Proc. Natl. Acad.
Sci. 110, E5016–E5024. doi: 10.1073/pnas.1314557110
Goldin, A. L., and Escayg, A. (2010). Sodium channel SCN1A and epilepsy:
mutations and mechanisms. Epilepsia 51:16. doi: 10.1111/j.1528-
1167.2010.02640.x
Goldschen-Ohm, M. P., Capes, D. L., Oelstrom, K. M., and Chanda, B. (2013).
Multiple pore conformations driven by asynchronous movements of voltage
sensors in a eukaryotic sodium channel. Nat. Commun. 4, 1350. doi: 10.1038/
ncomms2356
Gorman, K. M., and King, M. D. (2017). SCN2A p.Ala263Val Variant a Phenotype
of Neonatal Seizures Followed by Paroxysmal Ataxia in Toddlers. Pediatr.
Neurol. 67, 111–112. doi: 10.1016/j.pediatrneurol.2016.11.008
Grinton, B. E., Heron, S. E., Pelekanos, J. T., Zuberi, S. M., Kivity, S., Afawi, Z.,
et al. (2015). Familial neonatal seizures in 36 families: Clinical and genetic
features correlate with outcome. Epilepsia 56, 1071–1080. doi: 10.1111/
epi.13020
Guerrini, R., Cellini, E., Mei, D., Metitieri, T., Petrelli, C., Pucatti, D., et al. (2010).
Variable epilepsy phenotypes associated with a familial intragenic deletion of
the SCN1A gene. Epilepsia 51, 2474–2477. doi: 10.1111/j.1528-
1167.2010.02790.x
Hackenberg, A., Baumer, A., Sticht, H., Schmitt, B., Kroell-Seger, J., Wille, D., et al.
(2014). Infantile Epileptic Encephalopathy, Transient Choreoathetotic
Movements, and Hypersomnia due to a De Novo Missense Mutation in the
SCN2A Gene. Neuropediatrics 45, 261–264. doi: 10.1055/s-0034-1372302August 2020 | Volume 11 | Article 1276
Menezes et al. Epilepsy-Related Nav Channelopathies: A ReviewHaginoya, K., Togashi, N., Kaneta, T., Hino-Fukuyo, N., Ishitobi, M., Kakisaka, Y.,
et al. (2018). [18F]fluorodeoxyglucose-positron emission tomography study of
genetically confirmed patients with Dravet syndrome. Epilepsy Res. 147, 9–14.
doi: 10.1016/j.eplepsyres.2018.08.008
Hains, B. C., Klein, J. P., Saab, C. Y., Craner, M. J., Black, J. A., and Waxman, S. G.
(2003). Upregulation of sodium channel Nav1.3 and functional involvement in
neuronal hyperexcitability associated with central neuropathic pain after spinal
cord injury. J. Neurosci. 23, 8881–8892. doi: 10.1523/jneurosci.23-26-
08881.2003
Halvorsen, M., Petrovski, S., Shellhaas, R., Tang, Y., Crandall, L., Goldstein, D.,
et al. (2016). Mosaic mutations in early-onset genetic diseases. Genet. Med. 18,
746–749. doi: 10.1038/gim.2015.155
Han, J. Y., Jang, J. H., Lee, I. G., Shin, S., and Park, J. (2017). A novel inherited
mutation of SCN8a in a korean family with benign familial infantile epilepsy
using diagnostic exome sequencing. Ann. Clin. Lab. Sci. 47, 747–753.
Han, C., Dib-Hajj, S. D., Lin, Z., Li, Y., Eastman, E. M., Tyrrell, L., et al. (2009).
Early- and late-onset inherited erythromelalgia: genotypephenotype
correlation. Brain 132, 1711–1722. doi: 10.1093/brain/awp078
Hammer, M. F., Wagnon, J. L., Mefford, H. C., Meisler, M. H., et al. (2016).
“SCN8A-Related Epilepsy with Encephalopathy,” in GeneReviews® [Internet].
Eds. M. P. Adam, H. H. Ardinger and R. A. Pagon (Seattle (WA): University of
Washington).
Harkin, L. A., McMahon, J. M., Iona, X., Dibbens, L., Pelekanos, J. T., Zuberi, S. M.,
et al. (2007). The spectrum of SCN1A-related infantile epileptic
encephalopathies. Brain 130, 843–852. doi: 10.1093/brain/awm002
Haug, K., Hallmann, K., Rebstock, J., Dullinger, J., Muth, S., Haverkamp, F., et al.
(2001). The voltage-gated sodium channel gene SCN2A and idiopathic generalized
epilepsy. Epilepsy Res. 47, 243–246. doi: 10.1016/S0920-1211(01)00312-6
Haufe, V., Camacho, J. A., Dumaine, R., Günther, B., Bollensdorff, C., von
Banchet, G. S., et al. (2005). Expression pattern of neuronal and skeletal
muscle voltage-gated Na+ channels in the developing mouse heart. J. Physiol.
564, 683–696. doi: 10.1113/jphysiol.2004.079681
Herlenius, E., Heron, S. E., Grinton, B. E., Keay, D., Scheffer, I. E., Mulley, J. C.,
et al. (2007). SCN2A mutations and benign familial neonatal-infantile seizures:
The phenotypic spectrum. Epilepsia 48, 1138–1142. doi: 10.1111/j.1528-
1167.2007.01049.x
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